var title_f19_62_20448="Amniotic band sequence with cranial defect";
var content_f19_62_20448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amniotic band sequence with cranial defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oblique axial image through the fetal head shows the orbits, but no ossified cranium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20448=[""].join("\n");
var outline_f19_62_20448=null;
var title_f19_62_20449="Cystocele and rectocele";
var content_f19_62_20449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystocele and rectocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20449=[""].join("\n");
var outline_f19_62_20449=null;
var title_f19_62_20450="Patient information: Repeated miscarriage (The Basics)";
var content_f19_62_20450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85800\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/52/17218\">",
"         Patient information: Miscarriage (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/17/36113\">",
"         Patient information: Threatened miscarriage (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/52/21314\">",
"         Patient information: Uterine fibroids (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/8/28803\">",
"         Patient information: Miscarriage (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/20/20804\">",
"         Patient information: Uterine fibroids (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Repeated miscarriage (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6251819\">",
"      <span class=\"h1\">",
"       What is repeated miscarriage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A miscarriage is when a pregnancy ends on its own before a woman has been pregnant for 20 weeks. &ldquo;Repeated miscarriage&rdquo; is the term doctors use when a woman has 2 or more miscarriages in a row.",
"     </p>",
"     <p>",
"      <strong>",
"       What causes repeated miscarriage?",
"      </strong>",
"      &ndash; In some cases, repeated miscarriage is caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chromosome problems in the fetus &ndash; A &ldquo;fetus&rdquo; is what a baby is called while it is growing inside a woman. Chromosomes are structures in cells that contain thousands of genes. Chromosome problems usually happen by chance. But sometimes they happen because the mother or father has a chromosome problem. They also happen more often in older mothers.",
"       </li>",
"       <li>",
"        Conditions in which something changes the shape of the inside of the uterus (",
"        <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        An autoimmune condition in the mother &ndash; When a woman has an autoimmune condition, her infection-fighting system attacks healthy tissue in her body instead of infections.",
"       </li>",
"       <li>",
"        Other medical conditions in the mother &ndash; Some of these include diabetes, thyroid disease, blood clotting problems, or hormone problems.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In many cases, though, doctors don&rsquo;t know why repeated miscarriage happens.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6251857\">",
"      <span class=\"h1\">",
"       How will my doctor figure out why I am having repeated miscarriage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To figure out why you are having repeated miscarriage, your doctor will:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Talk with you and ask about your past pregnancies, monthly periods, and medical conditions",
"       </li>",
"       <li>",
"        Do an exam, including a pelvic exam",
"       </li>",
"       <li>",
"        Do blood tests &ndash; These include tests to check your immune system, blood clotting system, and hormone levels. They also include tests to check for certain medical conditions, such as thyroid disease or diabetes.",
"       </li>",
"       <li>",
"        Do an imaging test to check your uterus &ndash; Your doctor can do different types of imaging tests to check your uterus. One common test is a special type of ultrasound. (An ultrasound uses sound waves to create images of the inside of the body.)",
"       </li>",
"       <li>",
"        Do a test to look inside your uterus &ndash; This involves having a thin tube with a camera and light on the end put into your vagina and up into your uterus.",
"       </li>",
"       <li>",
"        Do chromosome tests on you and the baby&rsquo;s father &ndash; Before and after the testing, you will talk with a genetic counselor. This is a person who specializes in genetic problems.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might have other tests, too, depending on your individual situation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6251874\">",
"      <span class=\"h1\">",
"       How is repeated miscarriage treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor finds a possible cause that can be treated, he or she will treat it. Treatment might help improve your chances of having a successful pregnancy.",
"     </p>",
"     <p>",
"      For example, problems in the uterus can sometimes be treated with surgery. Certain medical, immune, or hormone problems can sometimes be treated with medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6251889\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to avoid another miscarriage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no sure way to avoid having another miscarriage. But you might be able to lower your chances of having one by avoiding cigarettes, alcohol, caffeine, and any injury to your belly. You can also try to stay at a healthy weight.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6251904\">",
"      <span class=\"h1\">",
"       Will I be able to have a baby someday?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many women who have repeated miscarriage are able to have a baby in the future.",
"     </p>",
"     <p>",
"      Let your doctor know when you are planning to become pregnant and then as soon as you think you are pregnant. That way, he or she can treat you with hormones or other treatments. Also, your doctor will be able to monitor your pregnancy as much as possible so you can have a successful pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6251919\">",
"      <span class=\"h1\">",
"       How can I get support if I&rsquo;m having a hard time coping?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Having repeated miscarriage can be very tough. If you are having a hard time coping, talk to your doctor or nurse. He or she can help you find a counselor to talk to.",
"     </p>",
"     <p>",
"      Some people also find it helpful to go to a support group for people who are in the same situation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6251934\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=see_link\">",
"       Patient information: Miscarriage (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/17/36113?source=see_link\">",
"       Patient information: Threatened miscarriage (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=see_link\">",
"       Patient information: Uterine fibroids (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=see_link\">",
"       Patient information: Miscarriage (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       Patient information: Uterine fibroids (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/62/20450?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85800 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20450=[""].join("\n");
var outline_f19_62_20450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6251819\">",
"      What is repeated miscarriage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6251857\">",
"      How will my doctor figure out why I am having repeated miscarriage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6251874\">",
"      How is repeated miscarriage treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6251889\">",
"      Is there anything I can do on my own to avoid another miscarriage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6251904\">",
"      Will I be able to have a baby someday?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6251919\">",
"      How can I get support if I&rsquo;m having a hard time coping?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6251934\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85800\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=related_link\">",
"      Patient information: Miscarriage (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=related_link\">",
"      Patient information: Miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/17/36113?source=related_link\">",
"      Patient information: Threatened miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=related_link\">",
"      Patient information: Uterine fibroids (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_62_20451="Isosulfan blue: Patient drug information";
var content_f19_62_20451=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Isosulfan blue: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/26/420?source=see_link\">",
"     see \"Isosulfan blue: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5577185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lymphazurin&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691283",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before a lymphography.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to isosulfan, triphenylmethane, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine to blue or green.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12030 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-043A92644E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20451=[""].join("\n");
var outline_f19_62_20451=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5577185\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011855\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011854\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011859\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011860\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011862\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011857\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011858\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011863\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011864\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/26/420?source=related_link\">",
"      Isosulfan blue: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_62_20452="Levorphanol: Patient drug information";
var content_f19_62_20452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Levorphanol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/22/29029?source=see_link\">",
"     see \"Levorphanol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702386",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to levorphanol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10806 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20452=[""].join("\n");
var outline_f19_62_20452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012330\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012329\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012334\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012335\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012337\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012332\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012333\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012338\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012339\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/22/29029?source=related_link\">",
"      Levorphanol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_62_20453="Hemochromatosis - low power Perls";
var content_f19_62_20453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemochromatosis in a 36-year-old woman (low power, Perl's iron stain)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a huge amount of iron (blue) in the parenchyma of this cirrhotic liver. Note the paucity of iron in the areas of scarring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20453=[""].join("\n");
var outline_f19_62_20453=null;
var title_f19_62_20454="Zellweger syndrome";
var content_f19_62_20454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Four patients with Zellweger (cerebrohepatorenal syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 566px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the high forehead, epicanthal folds, and hypoplasia of supraorbital ridges and midface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hans Zellweger, MD. Reproduced with permission from: Behrman, RE, Kliegman, RM, Jenson, HB (Eds). Nelson Textbook of Pediatrics, 17th Edition, Saunders 2004. p.439. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20454=[""].join("\n");
var outline_f19_62_20454=null;
var title_f19_62_20455="Polymorphous light eruption";
var content_f19_62_20455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Polymorphous light eruption",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/62/20455/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/62/20455/contributors\">",
"     Craig A Elmets, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/62/20455/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/62/20455/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/62/20455/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/62/20455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/62/20455/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/62/20455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphous light eruption (PMLE) is the most common idiopathic photodermatosis; it is sometimes called \"sun poisoning\" or &ldquo;sun allergy&rdquo;. PMLE usually presents as a non-scarring, pruritic rash in sun exposed areas. It appears hours to days after sun exposure and persists for several days before subsiding. A characteristic feature of PMLE is that it is most severe in the spring and early summer, moderates as the summer progresses, and resolves in the autumn or winter, only to recur the next spring. Juvenile spring eruption is a variant of PMLE. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Juvenile spring eruption (PMLE variant)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An overview of cutaneous photosensitivity and a review of other photodermatoses are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=see_link\">",
"     \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of PMLE typically occurs within the first three decades of life, and a female preponderance is reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Fair-skinned individuals are the most commonly affected, although PMLE can develop in individuals of all ethnicities and skin types [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/3\">",
"     3",
"    </a>",
"    ]. It occurs more frequently in temperate areas. Several studies have indicated that the prevalence of PMLE is inversely related to the latitude, ranging from 1 percent in Singapore to 20 percent in Sweden [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/1,2,4-6\">",
"     1,2,4-6",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    PMLE is a recurrent condition that may persist for years. However, the severity often improves with time. In a follow-up study of 114 patients with PMLE, 57 percent of patients noted decreasing sun sensitivity over the course of seven years, including 12 patients (9 percent) who reported complete resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both ultraviolet A (UVA) and ultraviolet B (UVB) radiation, and occasionally visible light, have been implicated in the development of PMLE [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/8\">",
"     8",
"    </a>",
"    ]. In most studies, a higher proportion of patients develops the disease in response to UVA than UVB [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/2\">",
"     2",
"    </a>",
"    ]. The eruption may be influenced by the dose and frequency of the UV radiation as well as by the extent and site of irradiated skin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/9\">",
"     9",
"    </a>",
"    ]. PMLE occurring after exposure to UVC radiation generated from welding arcs has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\", section on 'Phototesting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with PMLE appear to have a genetic susceptibility, as evidenced by increased concordance in monozygotic twins [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, a positive family history is present in 15 to 46 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. Genetic modeling of PMLE in families with photosensitivity disorders suggests a dominant mode of inheritance with low penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/13\">",
"     13",
"    </a>",
"    ]. No gene locus has been associated with PMLE. Candidate gene analysis has been inconclusive despite investigating IL-10, FCGR2A, SELE, ICAM-1, IL1-alpha, IL1-beta, IL1RN and TNF-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PMLE has many features in common with delayed-type hypersensitivity (DTH) responses in the skin, suggesting that it may be a cell-mediated immune response to unknown cutaneous photo-induced antigen(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/15\">",
"     15",
"    </a>",
"    ]. Timed biopsy specimens taken after solar-simulated irradiation displayed perivascular infiltrates of CD4+ T lymphocytes within a few hours and CD8+ T lymphocytes within days [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/16\">",
"     16",
"    </a>",
"    ]. Increased numbers of dermal and epidermal Langerhans cells and dermal macrophages were also noted. In addition, expression of E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) on endothelial cells and keratinocytes has also been observed, further supporting the relationship between PMLE and DTH reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In healthy individuals, exposure to ultraviolet radiation has a suppressive effect on T-cell immune responses in the skin. There is evidence to suggest that in patients with PMLE, this immunosuppressive effect of UV does not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. It has been postulated that this abnormal response to UV exposure permits PMLE patients to develop an inflammatory response to an endogenous photo-induced antigen, which would not occur in the general population. The photoantigen responsible for PMLE has not been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of PMLE characteristically occurs in the spring and early summer. When it occurs in winter, it usually results from tanning bed exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/22\">",
"     22",
"    </a>",
"    ] or vacationing in a sunny climate. The amount of exposure required to elicit PMLE ranges from 30 minutes to several hours. Skin lesions typically appear within hours, although they sometimes occur days after sun exposure. The eruption lasts one to several days and then resolves if further sun exposure is avoided. Occasionally, PMLE persists for weeks. Lesions heal without scarring. Sites of predilection for PMLE are sun-exposed areas, including the upper chest, the &ldquo;V&rdquo; of the neck, the back of the arms, and occasionally shoulders and lower legs. The disease occurs more frequently in skin that has been covered in the winter [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/3\">",
"     3",
"    </a>",
"    ]. Lesions often recur in the same anatomic locations.",
"   </p>",
"   <p>",
"    Several different types of skin lesions can occur in PMLE, but in a given individual the morphology is usually monomorphic and when there is a recurrence, lesions are usually identical to those observed during previous eruptions. Most commonly, patients present with pruritic, erythematous, or skin-colored papules or plaques in a symmetric distribution on sun-exposed skin (",
"    <a class=\"graphic graphic_picture graphicRef64270 graphicRef52975 graphicRef76995 graphicRef51455 \" href=\"UTD.htm?37/14/38122\">",
"     picture 1A-D",
"    </a>",
"    ). Papulovesicles, vesicles, bullae, or confluent edematous plaques (especially on the face) may also be seen. Less commonly, lesions resemble insect bites or erythema multiforme. In black and Asian patients, PMLE can also present as pinpoint papules [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In addition, pruritus without a cutaneous eruption has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/25\">",
"     25",
"    </a>",
"    ]. An eczematous form of PMLE does not exist, although eczematous changes can occur as a secondary response to rubbing and scratching.",
"   </p>",
"   <p>",
"    Systemic symptoms of fever, chills, headache, and nausea are rare but may accompany PMLE.",
"   </p>",
"   <p>",
"    Continued sun exposure may lead to increased tolerance to UVR and even to resolution of PMLE, a process referred to as \"hardening.\" By mid-summer, many patients are clear of the rash due to this phenomenon. The mechanism underlying hardening is not well understood, but is likely due to the cumulative effect of repeated small amounts of UV radiation resulting in increased melanin production, thickening of the stratum corneum, and, possibly, normalization of cutaneous cell-mediated immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of PMLE is usually based upon the patient's history and physical findings. It is important to exclude other photosensitive skin conditions (",
"    <a class=\"graphic graphic_table graphicRef57800 \" href=\"UTD.htm?15/1/15390\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H452346976\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Skin biopsy may be helpful in some cases, particularly to exclude other disorders. Histologic findings for PMLE are not diagnostic and require correlation with clinical presentation (",
"    <a class=\"graphic graphic_picture graphicRef65837 \" href=\"UTD.htm?10/40/10887\">",
"     picture 2",
"    </a>",
"    ). Focal epidermal spongiosis with focal lymphocyte exocytosis and a perivascular and periadnexal lymphohistiocytic infiltrate with occasional eosinophils and rare neutrophils may be seen. Papillary dermal edema, focal interface changes, and mild hydropic basal cell degeneration are present in more advanced lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/27\">",
"     27",
"    </a>",
"    ]. Direct immunofluorescence of skin biopsies is negative.",
"   </p>",
"   <p>",
"    Phototesting for the assessment of the minimal erythema dose (MED) is usually normal in patients with PMLE. Provocative phototesting, which tests for the appearance of PMLE lesions after repeated UV exposure, may be used to assist with diagnosis. Provocative phototesting is performed by repeatedly exposing the forearms or &ldquo;V&rdquo; of the neck to suberythemal doses of either UVA or UVB for one to four days. In over 60 percent of individuals with PMLE, this procedure will elicit clinical and histological features characteristic of PMLE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\", section on 'Diagnostic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452346976\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of PMLE includes other photosensitivity disorders, which are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef57800 \" href=\"UTD.htm?15/1/15390\">",
"     table 1",
"    </a>",
"    ) and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The earliest lesions of subacute cutaneous lupus erythematosus may resemble those of PMLE but are less pruritic. There is controversy as to whether patients with lupus erythematosus have a greater potential to have PMLE or whether the PMLE-like lesions are merely part of the photosensitive phenomenon observed in patients with lupus erythematosus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H15#H15\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Photosensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with mild PMLE do not seek medical attention, and chronic sun exposure may eventually prevent eruptions via the \"hardening\" phenomenon. For patients who desire treatment, options can be divided into first-line, second-line, and third-line therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/28\">",
"     28",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     First-line therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sun protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sun protection is first-line therapy for patients with PMLE and includes sun avoidance, sun protective clothing, and sunscreens. Sunscreens should be broad spectrum, with both UVA and UVB protection. A sunscreen with an SPF (sun protection factor) of at least 30 should be regularly applied [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\", section on 'Photoprotection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Products containing photostabilized avobenzone or ecamsule (Mexoryl SX) offer improved protection against UVA, and have been effective in preventing PMLE eruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Sunscreens that contain the non-micronized form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    or titanium dioxide also offer photoprotection that extends throughout the UV and into the visible spectrum. Examples of broad spectrum sunscreens containing photostabilized avobenzone or ecamsule, or zinc oxide and titanium oxide are provided (",
"    <a class=\"graphic graphic_table graphicRef58215 \" href=\"UTD.htm?8/51/9019\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have evaluated the efficacy of topical corticosteroids for PMLE. Clinical experience suggests that potent topical corticosteroids (groups one to three) (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 3",
"    </a>",
"    ) may be used for symptomatic relief, and may be sufficient pharmacologic therapy for mild cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/28\">",
"     28",
"    </a>",
"    ]. Facial lesions should be treated with lower potency topical corticosteroids (groups six to seven).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Second-line therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic phototherapy with low dose PUVA (psoralens plus UVA) or UVB in early spring to induce tolerance to sun exposure may be an option for patients who are expected to develop significant symptoms during the spring or summer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/28,33-35\">",
"     28,33-35",
"    </a>",
"    ]. Treatments are usually given two to three times per week over five to six weeks.",
"   </p>",
"   <p>",
"    PUVA therapy is superior to broadband UVB. In one randomized trial, treatment was successful in 92 percent of patients treated with PUVA, compared with 62 percent of patients treated with broadband UVB [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast, a small randomized trial showed narrowband UVB to be as effective as PUVA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/34\">",
"     34",
"    </a>",
"    ]. Because narrowband UVB is easier to administer, it is often preferred to PUVA therapy for patients with PMLE. Narrowband UVB phototherapy can be administered three times per week, starting with a dose equivalent to 50 to 70 percent of the MED. The dose is increased during subsequent treatments as tolerated by the patient.",
"   </p>",
"   <p>",
"    Treatment-induced exacerbations may occur early in the course of phototherapy. If these occur, potent topical corticosteroids (groups one to three) (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 3",
"    </a>",
"    ) or a short course of oral glucocorticoid therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1 mg per kg for 7 to 10 days) may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/28,36\">",
"     28,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids are occasionally prescribed for acute episodes of PMLE. In one trial, 21 patients were randomly assigned to take either 25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    or placebo at the first sign of PMLE during a sunny vacation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/37\">",
"     37",
"    </a>",
"    ]. If patients noted improvement, the initial treatment was continued until symptoms resolved or for a maximum of seven days. Patients were instructed to transfer to the other therapy if no improvement occurred after 48 hours.",
"   </p>",
"   <p>",
"    During the trial, 10 patients initiated study medication. Eight of the patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , five as initial therapy, and three as a second therapy after failure of the placebo. No patients who were initially treated with prednisolone transferred to the placebo. Treatment with prednisolone reduced the mean time to resolution of itch (5.4 versus 2.8 days) and rash (7.8 versus 4.2 days). The authors concluded that 25 mg of prednisolone for four to five days is an effective therapy for patients who suffer from occasional outbreaks of PMLE. Slightly longer treatment courses may be useful in some cases.",
"   </p>",
"   <p>",
"    Frequent courses of systemic glucocorticoids are not recommended due to associated potential side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Third line therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimalarials are useful for the treatment of some photosensitive disorders, including cutaneous lupus erythematosus, porphyria cutanea tarda, and dermatomyositis. Small randomized trials have demonstrated modest improvement in PMLE with antimalarials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anecdotal reports suggest effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/40\">",
"     40",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/41\">",
"     41",
"    </a>",
"    ]. However, these agents should be considered only in severely affected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     Beta-carotene",
"    </a>",
"    , a vitamin A precursor with photoprotective properties, has been investigated as a therapeutic agent for PMLE. In a randomized cross-over trial for prevention of symptoms, beta-carotene was more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/38\">",
"     38",
"    </a>",
"    ]. However, in most studies, the benefit of oral carotenoids has been minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/28,42\">",
"     28,42",
"    </a>",
"    ]. Beta-carotene is not as effective as PUVA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/43\">",
"     43",
"    </a>",
"    ]. The 1,25-dihydroxyvitamin D analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/54/5988?source=see_link\">",
"     calcipotriol",
"    </a>",
"    has been investigated as a preventive agent in PMLE. In a randomized placebo-controlled intraindividual half body trial involving 13 patients, calcipotriol cream significantly inhibited the severity of PMLE lesions on photoprovocation testing, suggesting that it may be of therapeutic benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     JUVENILE SPRING ERUPTION (PMLE VARIANT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"juvenile spring eruption\" was first proposed in 1954 for a recurrent springtime eruption on the ears of young boys [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/45\">",
"     45",
"    </a>",
"    ]. This disorder was found to affect approximately 7 percent of school-aged children in New Zealand [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/46\">",
"     46",
"    </a>",
"    ]. A family history may be positive in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients often present in childhood or early adolescence, but initial presentation in young adulthood has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20455/abstract/48\">",
"     48",
"    </a>",
"    ]. The lesions are typically erythematous scaly papules or bullae. They occur on the ears (",
"    <a class=\"graphic graphic_picture graphicRef55229 graphicRef68969 \" href=\"UTD.htm?10/4/10313\">",
"     picture 3A-B",
"    </a>",
"    ), face, and dorsal hands.",
"   </p>",
"   <p>",
"    Onset occurs in the spring, and symptoms resolve within several weeks, not to recur until the following spring. Boys are more commonly affected than girls. It has been postulated that this is related to shorter haircuts that expose their ears.",
"   </p>",
"   <p>",
"    The diagnosis is typically made on a clinical basis. The differential diagnosis includes herpes simplex viral (HSV) infection and hydroa vacciniforme. Viral cultures may be performed to rule out HSV, but the bilateral localization of juvenile spring eruption is uncommon in HSV infection. Predominantly vesicular lesions that heal with scarring and the lack of predilection for the ears are features more characteristic of hydroa vacciniforme.",
"   </p>",
"   <p>",
"    Treatment of juvenile spring eruption is not always necessary due to the transient nature of the disease. Topical corticosteroids may be effective to reduce inflammation. It is important to emphasize sun protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polymorphous light eruption (PMLE) is the most common idiopathic photodermatosis. Disease onset usually occurs during the first three decades. Individuals with fair skin are more likely to develop the disorder. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      UVA is the most common inciting spectrum of light, but UVB and visible light may also provoke PMLE in some patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PMLE is characterized by pruritic papules, papulovesicles, or plaques that appear hours or days after sun exposure and persist for days. Systemic symptoms are rare. Continued sun exposure characteristically leads to suppression of the condition over time. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is primarily based upon the patient's history and physical findings. In some cases skin biopsy or provocative phototesting may also be indicated. The differential diagnosis includes lupus erythematosus, erythropoietic protoporphyria and solar urticaria (",
"      <a class=\"graphic graphic_table graphicRef57800 \" href=\"UTD.htm?15/1/15390\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary treatment for PMLE includes sun avoidance, sun-protective clothing, and sunscreen. Broad spectrum sunscreens with an SPF of at least 30 should be regularly used. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with active lesions, we suggest treatment with potent topical corticosteroids (groups one to three (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 3",
"      </a>",
"      )) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative in patients with infrequent exacerbations, particularly those who require rapid improvement, is a short course of systemic glucocorticoids. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop frequent exacerbations during the spring and summer, we suggest prophylactic phototherapy in early spring (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Juvenile spring eruption is a variant of PMLE that is manifested by erythematous papules or bullae typically on ears of children or adolescents after sun exposure. Symptoms are self-limited and resolve within several weeks. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Juvenile spring eruption (PMLE variant)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/1\">",
"      Morison WL, Stern RS. Polymorphous light eruption: a common reaction uncommonly recognized. Acta Derm Venereol 1982; 62:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/2\">",
"      H&ouml;nigsmann H. Polymorphous light eruption. Photodermatol Photoimmunol Photomed 2008; 24:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/3\">",
"      Stratigos AJ, Antoniou C, Katsambas AD. Polymorphous light eruption. J Eur Acad Dermatol Venereol 2002; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/4\">",
"      Ros AM, Wennersten G. Current aspects of polymorphous light eruptions in Sweden. Photodermatol 1986; 3:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/5\">",
"      Pao C, Norris PG, Corbett M, Hawk JL. Polymorphic light eruption: prevalence in Australia and England. Br J Dermatol 1994; 130:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/6\">",
"      Khoo SW, Tay YK, Tham SN. Photodermatoses in a Singapore skin referral centre. Clin Exp Dermatol 1996; 21:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/7\">",
"      Jans&eacute;n CT, Karvonen J. Polymorphous light eruption. A seven-year follow-up evaluation of 114 patients. Arch Dermatol 1984; 120:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/8\">",
"      Boonstra HE, van Weelden H, Toonstra J, van Vloten WA. Polymorphous light eruption: A clinical, photobiologic, and follow-up study of 110 patients. J Am Acad Dermatol 2000; 42:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/9\">",
"      H&ouml;lzle E, Plewig G, Hofmann C, Roser-Maass E. Polymorphous light eruption. Experimental reproduction of skin lesions. J Am Acad Dermatol 1982; 7:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/10\">",
"      Majoie IM, van Weelden H, Sybesma IM, et al. Polymorphous light eruption-like skin lesions in welders caused by ultraviolet C light. J Am Acad Dermatol 2010; 62:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/11\">",
"      Millard TP, Bataille V, Snieder H, et al. The heritability of polymorphic light eruption. J Invest Dermatol 2000; 115:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/12\">",
"      Guarrera M, Micalizzi C, Rebora A. Heterogeneity of polymorphous light eruption: a study of 105 patients. Arch Dermatol 1993; 129:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/13\">",
"      McGregor JM, Grabczynska S, Vaughan R, et al. Genetic modeling of abnormal photosensitivity in families with polymorphic light eruption and actinic prurigo. J Invest Dermatol 2000; 115:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/14\">",
"      Millard TP, Kondeatis E, Cox A, et al. A candidate gene analysis of three related photosensitivity disorders: cutaneous lupus erythematosus, polymorphic light eruption and actinic prurigo. Br J Dermatol 2001; 145:229.",
"     </a>",
"    </li>",
"    <li>",
"     H&ouml;nigsmann H, Hojyo-Tomoka MT. Polymorphous light eruption, hydroa vacciniforme, and actinic prurigo. In: Photodermatology, Lim HW, H&ouml;nigsmann H, Hawk JLM (Eds), CRC Press, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/16\">",
"      Norris PG, Morris J, McGibbon DM, et al. Polymorphic light eruption: an immunopathological study of evolving lesions. Br J Dermatol 1989; 120:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/17\">",
"      Schornagel IJ, Sigurdsson V, Nijhuis EH, et al. Decreased neutrophil skin infiltration after UVB exposure in patients with polymorphous light eruption. J Invest Dermatol 2004; 123:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/18\">",
"      K&ouml;lgen W, van Meurs M, Jongsma M, et al. Differential expression of cytokines in UV-B-exposed skin of patients with polymorphous light eruption: correlation with Langerhans cell migration and immunosuppression. Arch Dermatol 2004; 140:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/19\">",
"      van de Pas CB, Kelly DA, Seed PT, et al. Ultraviolet-radiation-induced erythema and suppression of contact hypersensitivity responses in patients with polymorphic light eruption. J Invest Dermatol 2004; 122:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/20\">",
"      K&ouml;lgen W, Van Weelden H, Den Hengst S, et al. CD11b+ cells and ultraviolet-B-resistant CD1a+ cells in skin of patients with polymorphous light eruption. J Invest Dermatol 1999; 113:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/21\">",
"      Palmer RA, Friedmann PS. Ultraviolet radiation causes less immunosuppression in patients with polymorphic light eruption than in controls. J Invest Dermatol 2004; 122:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/22\">",
"      Rivers JK, Norris PG, Murphy GM, et al. UVA sunbeds: tanning, photoprotection, acute adverse effects and immunological changes. Br J Dermatol 1989; 120:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/23\">",
"      Kontos AP, Cusack CA, Chaffins M, Lim HW. Polymorphous light eruption in African Americans: pinpoint papular variant. Photodermatol Photoimmunol Photomed 2002; 18:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/24\">",
"      Chiam LY, Chong WS. Pinpoint papular polymorphous light eruption in Asian skin: a variant in darker-skinned individuals. Photodermatol Photoimmunol Photomed 2009; 25:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/25\">",
"      Dover JS, Hawk JL. Polymorphic light eruption sine eruption. Br J Dermatol 1988; 118:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/26\">",
"      Janssens AS, Pavel S, Out-Luiting JJ, et al. Normalized ultraviolet (UV) induction of Langerhans cell depletion and neutrophil infiltrates after artificial UVB hardening of patients with polymorphic light eruption. Br J Dermatol 2005; 152:1268.",
"     </a>",
"    </li>",
"    <li>",
"     Hawk JLM, Calonje E. The photosensitivity disorders. In: Lever's Histopathology of the Skin,, 9th ed, Elder DE (Ed), Lippincott Williams and Wilkins, Philadelphia 2005. p.365.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/28\">",
"      Ling TC, Gibbs NK, Rhodes LE. Treatment of polymorphic light eruption. Photodermatol Photoimmunol Photomed 2003; 19:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/29\">",
"      Proby CM, Baker CS, Morton O, Hawk JL. New broad-spectrum sunscreen for polymorphic light eruption. Lancet 1993; 341:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/30\">",
"      Allas S, Lui H, Moyal D, Bissonnette R. Comparison of the ability of 2 sunscreens to protect against polymorphous light eruption induced by a UV-A/UV-B metal halide lamp. Arch Dermatol 1999; 135:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/31\">",
"      Fourtanier A, Moyal D, Seit&eacute; S. Sunscreens containing the broad-spectrum UVA absorber, Mexoryl SX, prevent the cutaneous detrimental effects of UV exposure: a review of clinical study results. Photodermatol Photoimmunol Photomed 2008; 24:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/32\">",
"      DeLeo VA, Clark S, Fowler J, et al. A new ecamsule-containing SPF 40 sunscreen cream for the prevention of polymorphous light eruption: a double-blind, randomized, controlled study in maximized outdoor conditions. Cutis 2009; 83:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/33\">",
"      Addo HA, Sharma SC. UVB phototherapy and photochemotherapy (PUVA) in the treatment of polymorphic light eruption and solar urticaria. Br J Dermatol 1987; 116:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/34\">",
"      Bilsland D, George SA, Gibbs NK, et al. A comparison of narrow band phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. Br J Dermatol 1993; 129:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/35\">",
"      Murphy GM, Logan RA, Lovell CR, et al. Prophylactic PUVA and UVB therapy in polymorphic light eruption--a controlled trial. Br J Dermatol 1987; 116:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/36\">",
"      Man, I, Dawe, RS, Ibbotson, SH, et al. Is topical steroid effective in polymorphic light eruption? Br J Dermatol 2000; 143 (Suppl 57):113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/37\">",
"      Patel DC, Bellaney GJ, Seed PT, et al. Efficacy of short-course oral prednisolone in polymorphic light eruption: a randomized controlled trial. Br J Dermatol 2000; 143:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/38\">",
"      Jans&eacute;n CT. Oral carotenoid treatment in polymorphous light eruption: a cross-over comparison with oxychloroquine and placebo. Photodermatol 1985; 2:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/39\">",
"      Murphy GM, Hawk JL, Magnus IA. Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. Br J Dermatol 1987; 116:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/40\">",
"      Norris PG, Hawk JL. Successful treatment of severe polymorphous light eruption with azathioprine. Arch Dermatol 1989; 125:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/41\">",
"      Shipley DR, Hewitt JB. Polymorphic light eruption treated with cyclosporin. Br J Dermatol 2001; 144:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/42\">",
"      Corbett MF, Hawk JL, Herxheimer A, Magnus IA. Controlled therapeutic trials in polymorphic light eruption. Br J Dermatol 1982; 107:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/43\">",
"      Parrish JA, Le Vine MJ, Morison WL, et al. Comparison of PUVA and beta-carotene in the treatment of polymorphous light eruption. Br J Dermatol 1979; 100:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/44\">",
"      Gruber-Wackernagel A, Bambach I, Legat FJ, et al. Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D analogue in polymorphic light eruption. Br J Dermatol 2011; 165:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/45\">",
"      ANDERSON D, WALLACE HJ, HOWES EI. Juvenile spring eruption. Lancet 1954; 266:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/46\">",
"      Tan E, Eberhart-Phillips J, Sharples K. Juvenile spring eruption: a prevalence study. N Z Med J 1996; 109:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/47\">",
"      Berth-Jones J, Norris PG, Graham-Brown RA, et al. Juvenile spring eruption of the ears: a probable variant of polymorphic light eruption. Br J Dermatol 1991; 124:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20455/abstract/48\">",
"      Stratigos AJ, Antoniou C, Papadakis P, et al. Juvenile spring eruption: clinicopathologic features and phototesting results in 4 cases. J Am Acad Dermatol 2004; 50:S57.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6623 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-211.167.112.14-B91D0C0919-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20455=[""].join("\n");
var outline_f19_62_20455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H452346976\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      First-line therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sun protection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Second-line therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Third line therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      JUVENILE SPRING ERUPTION (PMLE VARIANT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/6623\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/6623|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/9/5269\" title=\"picture 1A\">",
"      PMLE forearms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/48/5893\" title=\"picture 1B\">",
"      PMLE neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/9/8338\" title=\"picture 1C\">",
"      PMLE hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/46/6882\" title=\"picture 1D\">",
"      PMLE face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/40/10887\" title=\"picture 2\">",
"      PMLE pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/14/38115\" title=\"picture 3A\">",
"      Juvenile spring eruption 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/24/4485\" title=\"picture 3B\">",
"      Juvenile spring eruption 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/6623|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/1/15390\" title=\"table 1\">",
"      Photosensitive disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/51/9019\" title=\"table 2\">",
"      Broad spectrum sunscreens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 3\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=related_link\">",
"      Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_62_20456="Tinea corporis - multiple lesions";
var content_f19_62_20456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55949%7EPC%2F66102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55949%7EPC%2F66102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea corporis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple annular erythematous plaques with peripheral scale are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea corporis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This annular lesion with a raised erythematous border, central clearing, and slight scale was consistent with tinea corporis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher, GR, Ludwig, S, Baskin, MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20456=[""].join("\n");
var outline_f19_62_20456=null;
var title_f19_62_20457="Ketoconazole (systemic): Pediatric drug information";
var content_f19_62_20457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketoconazole (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/58/28585?source=see_link\">",
"    see \"Ketoconazole (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/30/2533?source=see_link\">",
"    see \"Ketoconazole (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8120384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8120609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ketoconazole&reg;;",
"     </li>",
"     <li>",
"      Novo-Ketoconazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10501727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10503653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/58/28585?source=see_link\">",
"      see \"Ketoconazole (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children: 3.3-6.6 mg/kg/day once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prophylaxis for recurrence of mucocutaneous candidiasis with HIV infection: 5-10 mg/kg/day divided every 12-24 hours; maximum: 800 mg/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 200-400 mg/day as a single daily dose; maximum: 800 mg/day divided twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8120786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8120610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10503654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer with or without food or with juice; administer with food to decrease nausea and vomiting; administer 2 hours prior to antacids, didanosine, proton pump inhibitors, or H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonists to prevent decreased ketoconazole absorption; shake suspension well before use",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10503644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible fungal infections, including candidiasis, oral thrush, blastomycosis, coccidioidomycosis, histoplasmosis, paracoccidioidomycosis, chronic mucocutaneous candidiasis, as well as certain recalcitrant cutaneous dermatophytoses (FDA approved in ages &ge;2 years of age and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8120549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nizoral&reg; may be confused with Nasarel, Neoral&reg;, Nitrol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8120670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Bulging fontanelles, chills, depression, diarrhea, dizziness, fever, gynecomastia, headache, hemolytic anemia, hepatotoxicity, impotence, leukopenia, photophobia, somnolence, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10503645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketoconazole or any component; single agent in the treatment of CNS fungal infections (due to poor CNS penetration); concomitant administration of astemizole, terfenadine, cisapride, or oral triazolam",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10503648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gastric acidity is necessary for the dissolution and absorption of ketoconazole; avoid concomitant (within 2 hours) administration of antacids, H",
"     <sub>",
"      2",
"     </sub>",
"     blockers, anticholinergics.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10503646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has been associated with hepatotoxicity, including some fatalities",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; perform periodic liver function tests; use with caution in patients with impaired hepatic function; high doses of ketoconazole may depress adrenocortical function and decrease serum testosterone concentrations; concomitant use with cisapride is contraindicated due to the occurrence of ventricular arrhythmias",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Hypersensitivity reactions (including rare cases of anaphylaxis) have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8120688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP2A6 (moderate), CYP2B6 (weak), CYP2C19 (moderate), CYP2C8 (weak), CYP2C9 (strong), CYP2D6 (moderate), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8120689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Ketoconazole (Systemic) may increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Ketoconazole (Systemic). Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May enhance the adverse/toxic effect of Ketoconazole (Systemic). Specifically, there is a theoretical potential for additive effects on reducing endogenous steroid concentrations. Ketoconazole (Systemic) may increase the serum concentration of AtorvaSTATin. Management: Administer ketoconazole with atorvastatin cautiously, and monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities). Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: Ketoconazole (Systemic) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).  Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Quazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Boceprevir. Management: Limit maximum adult ketoconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in ketoconazole concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cinacalcet.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Cobicistat. Management: Limit ketoconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Ketoconazole (Systemic) may increase the serum concentration of Dabigatran Etexilate.  Management: Increase monitoring of any patient using this combination; dabigatran dose reduction may be needed in patients with moderate renal dysfunction; avoid the combination with severe renal dysfunction.  This combination is contraindicated in Canadian labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Darunavir. Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving darunavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Ketoconazole (Systemic) may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Domperidone: May enhance the QTc-prolonging effect of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Domperidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Ketoconazole (Systemic) may increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Ketoconazole (Systemic) may increase the serum concentration of Elvitegravir.  Management: Limit ketoconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Ketoconazole (Systemic) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Ketoconazole (Systemic) may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Ketoconazole (Systemic) may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Ketoconazole (Systemic) may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eszopiclone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Eszopiclone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Ketoconazole (Systemic) may increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Fingolimod. Ketoconazole (Systemic) may increase the serum concentration of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day ketoconazole may also require dose reduction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This specifically applies to oral antifungal administration, and the interaction may be different depending on specific dosage form being used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Ketoconazole (Systemic). Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Indinavir. Management: Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with ketoconazole.  Monitor for increased systemic effects (including adverse/toxic effects) of ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Ketoconazole (Systemic) may increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Ketoconazole (Systemic) may increase the serum concentration of Methadone.  Management: Methadone dose reduction may be necessary when used with ketoconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Ketoconazole (Systemic) may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Ketoconazole (Systemic) may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Ketoconazole (Systemic) may increase the serum concentration of Mirabegron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: Ketoconazole (Systemic) may increase the serum concentration of Praziquantel.  Management: Praziquantel dose may need to be reduced when used with ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine.  Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Repaglinide.  Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Ketoconazole (Systemic) may increase the serum concentration of Rilpivirine. Rilpivirine may decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Ketoconazole (Systemic). Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Ketoconazole (Systemic) may increase the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving saquinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Ketoconazole (Systemic) may increase the serum concentration of Sildenafil.  Management: Concurrent ketoconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Ketoconazole (Systemic) may increase the serum concentration of Sirolimus.  Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Solifenacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of SUNItinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Ketoconazole (Systemic) may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required when taken with ketoconazole due to elevated plasma concentrations of tacrolimus.  Monitor tacrolimus concentrations and clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Ketoconazole (Systemic) may increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Ketoconazole (Systemic) may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Ketoconazole (Systemic).  Management: Doses of ketoconazole greater than 200 mg/day are not recommended in patients receiving telaprevir.  Use extra caution when using these drugs in combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Temsirolimus.  Management: Temsirolimus dose adjustments will likely be needed when starting/stopping/changing ketoconazole.  Clinical data suggest temsirolimus (adult) dose reductions of around 50% should be considered, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase the serum concentration of Ketoconazole (Systemic). Management: Limit ketoconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Ketoconazole (Systemic) may increase the serum concentration of Vardenafil.  Management: Limit vardenafil dosing to a  maximum of 5 mg per 24 hours  in patients receiving ketoconazole 200 mg/day, and a maximum of 2.5 mg per 24 hours in patients receiving ketoconazole 400 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Ketoconazole (Systemic) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Zolpidem.  Management: Consider using a lower starting dose of zolpidem in patients receiving systemic azole antifungals. Monitor patients closely for increased magnitude and/or duration of zolpidem effects when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10503650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may increase ketoconazole absorption; administration with an acidic beverage (eg, Coca-Cola, Pepsi, citrus juice) increases ketoconazole absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8120649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8120650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were noted in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10501728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, signs of adrenal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10503651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alters the permeability of the cell wall; inhibits fungal biosynthesis of triglycerides and phospholipids; inhibits several fungal enzymes that results in a build-up of toxic concentrations of hydrogen peroxide",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10503652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid (~75%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Minimal penetration into the CNS; distributes to bile, saliva, urine, sweat, synovial fluid, lungs, liver, kidney, and bone marrow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 84% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Partially in the liver via CYP3A4 to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Decreases as pH of the gastric contents increases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, biphasic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alpha: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Terminal: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily in feces (57%) with smaller amounts excreted in urine (~13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10501729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/30/2533?source=see_link\">",
"      see \"Ketoconazole (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician of unusual fatigue, weakness, vomiting, dark urine, or yellowing of eyes; avoid alcohol",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F8120789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 20 mg/mL oral suspension may be made with tablets and one of three different vehicles (a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;, or a 1:4 mixture of cherry syrup and Simple Syrup, NF). Crush twelve 200 mg tablets in a mortar and reduce to a fine powder. Add 20 mL of chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;.  Stable for 60 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boon JM, Lafeber HN, Mannetje Ah, et al, \"Comparison of Ketoconazole Suspension and Nystatin in the Treatment of Newborns and Infants With Oral Candidosis,\"",
"      <i>",
"       Mycoses",
"      </i>",
"      , 1988, 32(6):312-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/62/20457/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Como JA and Dismukes WE, \"Oral Azole Drugs as Systemic Antifungal Therapy,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(4):263-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/62/20457/abstract-text/8272088/pubmed\" id=\"8272088\" target=\"_blank\">",
"        8272088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ginsburg AM, McCracken GH Jr, and Olsen K, &ldquo;Pharmacology of Ketoconazole Suspension in Infants and Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 23(5):787-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/62/20457/abstract-text/6307138/pubmed\" id=\"6307138\" target=\"_blank\">",
"        6307138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herrod HG, &ldquo;Chronic Mucocutaneous Candidiasis in Childhood and Complications of non-",
"      <i>",
"       Candida",
"      </i>",
"      Infection: A Report of the Pediatric Immunodeficiency Collaborative Study Group,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 116(3):377-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/62/20457/abstract-text/2308026/pubmed\" id=\"2308026\" target=\"_blank\">",
"        2308026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Anker JN, van Lingen RA, Koster M, et al, \"Insufficient Ketoconazole Concentrations in Preterm Infants With Fungal Infections,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 1993, 152(6):538.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/62/20457/abstract-text/8335029/pubmed\" id=\"8335029\" target=\"_blank\">",
"        8335029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16004 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20457=[""].join("\n");
var outline_f19_62_20457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120384\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120609\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501727\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503653\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120786\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120610\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503654\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503644\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120549\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120670\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503645\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503648\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503646\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120688\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120689\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503650\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120649\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120650\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501728\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503651\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503652\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501729\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120789\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16004\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16004|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/58/28585?source=related_link\">",
"      Ketoconazole (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/30/2533?source=related_link\">",
"      Ketoconazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38500?source=related_link\">",
"      Ketoconazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/51/34612?source=related_link\">",
"      Ketoconazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/26/10659?source=related_link\">",
"      Ketoconazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_62_20458="Pregnancy in women with sickle cell disease";
var content_f19_62_20458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy in women with sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/62/20458/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/62/20458/contributors\">",
"     Elliott P Vichinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/62/20458/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/62/20458/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/62/20458/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/62/20458/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/62/20458/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/62/20458/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/62/20458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most pregnancies complicated by maternal sickle cell disease (SCD) are likely to result in livebirth, these pregnancies are at increased risk of obstetrical and fetal complications, as well as medical complications of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. These risks are due, at least in part, to the metabolic demands, hypercoagulable state, and vascular stasis associated with pregnancy.",
"   </p>",
"   <p>",
"    Pregnancy-related issues in management of patients with SCD will be discussed here. General issues regarding clinical features, pathophysiology, diagnosis, and management of SCD are reviewed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"       \"Overview of the clinical manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=see_link\">",
"       \"Vasoocclusion in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"       \"Diagnosis of sickle cell syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"       \"Overview of the management of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1011610\">",
"    <span class=\"h1\">",
"     PREPREGNANCY ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risks of pregnancy for women with SCD and the fetus, preconceptional assessment and counseling, including referral to a genetic counselor, are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18428063\">",
"    <span class=\"h2\">",
"     Prepregnancy evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient&rsquo;s clinical history of pain events and hospitalizations should be reviewed, and a detailed evaluation should be performed because of the increased prevalence of end-organ dysfunction (eg, sickle nephropathy) in adults with SCD. This evaluation generally includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirmation of definitive diagnosis",
"     </li>",
"     <li>",
"      Measurement of baseline blood pressure, since hypertension may be due to sickle nephropathy and is a risk factor for stroke and development of superimposed preeclampsia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H26#H26\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Cerebrovascular events'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retinal evaluation to detect early proliferative sickle retinopathy, which may worsen during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H39#H39\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Retinopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemistry panel, urinalysis, and 24-hour protein excretion to determine baseline organ function, particularly sickle nephropathy. Knowledge of baseline parameters is important because both pregnancy and preeclampsia (which is common in SCD patients) may worsen renal function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      .) The author obtains a baseline 24-hour urine collection to determine creatinine clearance and protein excretion, but the protein-to-creatinine ratio on a spot urine sample is also acceptable [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Hemoglobin/hematocrit",
"      </span>",
"      and ferritin level. Women with SCD often have excessive iron stores, but a small proportion is iron deficient. Women with excessive iron stores should not receive vitamins with iron and should consider delaying pregnancy until they have been treated with iron chelators, which are contraindicated in pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H28#H28\">",
"       \"Overview of the management of sickle cell disease\", section on 'Excessive iron stores'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Baseline urine culture, because of the increased frequency of asymptomatic bacteriuria. Urinary tract infections are more common in sickle cell disease and more difficult to treat because of underlying renal papillary necrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=see_link&amp;anchor=H2#H2\">",
"       \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\", section on 'Asymptomatic bacteriuria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Baseline pulmonary function tests, including pulse oximetry, are recommended because of the increased risk of pulmonary embolism, acute chest syndrome, and bronchoreactive lung disease in pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H35#H35\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Pulmonary complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatitis B and C screening to assess risk of perinatal transmission. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22777?source=see_link\">",
"       \"Pregnancy in women with pre-existing chronic liver disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Echocardiogram as a screening test for pulmonary hypertension and early cardiac dysfunction, which are associated with increased mortality in SCD and pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"       \"Acquired heart disease and pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H28#H28\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Cardiac complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Red cell genotyping and screening for red cell alloimmunization to identify patients with multiple red cell alloantibodies who may be difficult to match for transfusion and may be at risk for hemolytic disease of the fetus and newborn. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"       \"Significance of minor red blood cell antibodies during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testing partner for hemoglobinopathy. The risk of SCD in offspring is 50 percent if the biologic father is heterozygous; the risk is 100 percent if he is homozygous. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"       \"Diagnosis of sickle cell syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1482781\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to a genetic counselor is useful to discuss the type and risk of inherited disease in offspring, and the variability of phenotype. This is also a good time to discuss the range of pregnancy options, as appropriate, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of donor sperm from a male without hemoglobinopathy. This will ensure that the offspring will be heterozygous (ie, have sickle cell trait), which is essentially a benign carrier state. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11433?source=see_link\">",
"       \"Donor insemination\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=see_link\">",
"       \"Sickle cell trait\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preimplantation genetic diagnosis for selection of embryos without SCD",
"     </li>",
"     <li>",
"      Prenatal diagnosis, with possible termination of an affected pregnancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assisted reproductive technology provides two additional options. A gestational carrier pregnancy allows the patient to avoid the maternal and fetal risks associated with pregnancy complicated by SCD. A gestational carrier is a woman who agrees to carry a pregnancy for another woman (intended mother). The intended mother provides the egg and the intended father provides the sperm; egg donors or sperm donors without hemoglobinopathy can also be used. In vitro fertilization (IVF) creates an embryo, which is transferred into the uterus of the gestational carrier. The gestational carrier has no genetic connection to the embryo. Another approach is a surrogate pregnancy. The surrogate, who does not have a hemoglobinopathy, undergoes intrauterine insemination (IUI) of sperm from the intended father (or a sperm donor). Therefore, the surrogate carrier has a genetic, as well as a gestational, connection to the embryo. Adoption is another option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1483024\">",
"    <span class=\"h3\">",
"     Preimplantation diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preimplantation genetic diagnosis (PGD) of SCD is possible and is an option for couples whose goal is to only establish pregnancies in which the child is unaffected by SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/6\">",
"     6",
"    </a>",
"    ]. For PGD, the couple must conceive via in vitro fertilization (IVF). Preimplantation embryos are biopsied and only those unaffected by SCD are selected for transfer into the uterus. If HLA typing is also performed, unaffected embryos who are also HLA identical to an affected sibling can be selected to allow future stem cell transplantation of that sibling. PGD is expensive and may decrease the chance of achieving pregnancy and livebirth compared with natural conception, but there does not appear to be any long-term harm to offspring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1483082\">",
"    <span class=\"h3\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the fetus for sickle hemoglobin, as well as other hemoglobinopathies, can be performed in at-risk pregnancies using invasive techniques, such as chorionic villus biopsy at 10 to 13 weeks of gestation or amniocentesis as early as 15 to 16 weeks. Fetal blood sampling can be performed after 20 weeks of gestation, but is associated with a higher risk of fetal loss (1 to 2 percent) and has no advantage over other methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24999?source=see_link\">",
"     \"Prenatal testing for the hemoglobinopathies and thalassemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninvasive detection of fetal SCD by evaluation of cell-free fetal DNA in maternal plasma is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This test is not commercially available.",
"   </p>",
"   <p>",
"    A variety of personal factors influence parental decisions about termination of pregnancy when test results indicate an affected fetus. Early gestational age at the time of diagnosis also appears to affect this decision [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/9\">",
"     9",
"    </a>",
"    ]. While pregnancy termination is usually well tolerated in SCD, the disease is a risk factor for increased severity of termination complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/10\">",
"     10",
"    </a>",
"    ]. In our experience, these women have a very high incidence of acute painful episodes after pregnancy termination. Therefore, we suggest an inpatient procedure with intravenous hydration before and for 24 hours after the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link\">",
"     \"Overview of pregnancy termination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18428094\">",
"    <span class=\"h2\">",
"     Management of medications and immunization",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Immunization",
"      </strong>",
"      &mdash; Immunization status should be reviewed and updated, as needed, to comply with current guidelines. Polyvalent pneumococcal, Haemophilus influenza type B, and meningococcal vaccines are recommended for pregnant patients with SCD. Pregnancy should be avoided for at least four weeks after administration of a live vaccine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"       \"Approach to immunizations in healthy adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"       \"Immunizations during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; Folic acid supplementation (0.4 to 0.8",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is recommended for all women of reproductive age to reduce the risk of neural tube defects in offspring. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link\">",
"       \"Folic acid for prevention of neural tube defects\"",
"      </a>",
"      .) There is consensus opinion among experts that the dose should be higher in women with SCD to accommodate this requirement, as well as routine pregnancy requirements and SCD requirements related to hemolysis. No dose finding studies have been performed. A dose of 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      has been recommended as likely to satisfy all of these needs [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"       4",
"      </a>",
"      ]. This is higher than the dose found in prenatal vitamins (1 mg).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       Hydroxyurea",
"      </a>",
"      &mdash; Many patients will be on hydroxyurea (hydroxycarbamide) therapy. Exposure to hydroxyurea, alone or in combination with other drugs, has been reported in fewer than 100 human pregnancies, including approximately 40 first trimester exposures [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/11\">",
"       11",
"      </a>",
"      ]. An increase in major congenital defects was not observed in these limited human data, but has been reported in animal studies. Given the relatively small number of exposed pregnancies and the observation that hydroxyurea produced malformations in animal studies, it is prudent to discontinue hydroxyurea three months before conception [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"       \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Iron chelators",
"      </strong>",
"      &mdash; Women on iron chelation therapy may continue this therapy until they conceive, but it should be discontinued at that time. In experimental animal studies,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      did not increase the risk of congenital anomalies at doses lower than those used in humans, but",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      was associated with congenital anomalies in some animal studies [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Data from exposure in humans are limited [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/13\">",
"       13",
"      </a>",
"      ], especially for deferasirox, but no toxic or teratogenic effects have been reported. Both drugs are FDA pregnancy category C (",
"      <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"       table 1",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       Deferiprone",
"      </a>",
"      is pregnancy category D. Untreated women with excessive iron stores should consider delaying pregnancy until treatment has been completed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H28#H28\">",
"       \"Overview of the management of sickle cell disease\", section on 'Excessive iron stores'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       ACE inhibitors and ARBs",
"      </strong>",
"      &mdash; Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are teratogenic and should not be used during pregnancy. Women using these drugs for treatment of hypertension should be switched to another drug, ideally at least one month before they attempt to conceive. Women using these drugs for prevention of progression of proteinuric or microalbuminuric kidney disease should be counseled about early detection of pregnancy. In this situation, they may continue to use these drugs but should discontinue the ACE inhibitor or ARB if their menstrual period is delayed by more than two days, at which time they should have a sensitive pregnancy test and consult with their physician. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Prophylactic penicillin",
"      </strong>",
"      &mdash; Prophylactic penicillin therapy may be continued during pregnancy. Penicillin has an excellent maternal-fetal safety profile for use in pregnancy. We do not routinely initiate penicillin prophylaxis because of pregnancy but continue it in patients who are already taking prophylaxis. In England, penicillin prophylaxis is recommended based on the associated hyposplenism [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/14\">",
"       14",
"      </a>",
"      ], but evidence supporting this approach in pregnant women is not available.",
"     </li>",
"     <li>",
"      <strong>",
"       Analgesia",
"      </strong>",
"      &mdash; Pain can be managed using standard therapies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17114?source=see_link\">",
"       \"Acute pain management in adults with sickle cell disease\"",
"      </a>",
"      .) However, nonsteroidal antiinflammatory drugs (NSAIDs) may interfere with ovulation, thereby reducing the probability of conception. Whether NSAID use in the first trimester increases the risk of miscarriage, cardiac defects, or gastroschisis is unclear; epidemiologic studies have reported conflicting results [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"      </a>",
"      .) NSAIDs are generally avoided after 30 weeks of gestation because of the risk of premature narrowing or closure of the ductus arteriosus. (See",
"      <a class=\"local\" href=\"#H1058980\">",
"       'Management of acute painful episodes'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18429102\">",
"    <span class=\"h2\">",
"     Counseling about medical, obstetrical, and infant outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on pregnancy and SCD outcomes is limited because of limitations of the available studies, which are mostly small, old, retrospective, and often do not have appropriate control groups, consistent definitions, or adequate ascertainment of pregnancy outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18429428\">",
"    <span class=\"h3\">",
"     SCD course during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is consistent evidence that anemia and vasoocclusive or painful crises occur more often in pregnancy and are the most common maternal SCD complications associated with pregnancy, occurring in over 50 percent of pregnant women with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/15-22\">",
"     15-22",
"    </a>",
"    ]. Painful crises are more common with advancing pregnancy and postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest data set of SCD outcomes in pregnant women is the Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project of the US Agency for Healthcare Research and Quality, which analyzed all pregnancy-related discharges with a diagnosis of SCD for the years 2000-2003, and included almost 18,000 deliveries to women with SCD and 17 million deliveries to women without the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/3\">",
"     3",
"    </a>",
"    ]. Compared with women without SCD, women with SCD were at increased risk of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal death &ndash; While women with SCD accounted for 0.1 percent of the pregnancies, they accounted for 1 percent of all maternal deaths. There were 10 deaths in the SCD group (mortality 72 deaths per 100,000 deliveries versus 12.7 deaths per 100,000 deliveries in women without SCD).",
"     </li>",
"     <li>",
"      Transfusion (OR 22.5; 95% CI 18.7-27.0)",
"     </li>",
"     <li>",
"      Systemic inflammatory response syndrome (SIRS; OR 12.6; 95% CI 2.1-13.6)",
"     </li>",
"     <li>",
"      Pneumonia (OR 9.8; 95% CI 8.0-12.0)",
"     </li>",
"     <li>",
"      Sepsis (OR 6.8; 95% CI 4.4-10.5)",
"     </li>",
"     <li>",
"      Asymptomatic bacteriuria (OR 6.8, 95% CI 3.1-14.9)",
"     </li>",
"     <li>",
"      Cerebral vein thrombosis (OR 4.9; 95% CI 2.2-10.9)",
"     </li>",
"     <li>",
"      Deep vein thrombosis (OR 2.5; 95% CI 1.5-4.1)",
"     </li>",
"     <li>",
"      Genitourinary tract infection (OR 2.3, 95% CI 1.9-2.7)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was no statistical difference in rates of stroke (OR 2.0; 95% CI 0.6-6.9), pyelonephritis (OR 1.3; 95% CI 1.0-1.8), pulmonary embolus (OR 1.7; 95% CI 0.9-3.1), or myocardial infarction (OR 0). The findings in this report need to be interpreted cautiously because of limitations in the quality of the data, which were based on discharge codes and drawn exclusively from discharge record abstractions.",
"   </p>",
"   <p>",
"    There are no studies this large comparing medical complication rates in pregnant versus nonpregnant women with SCD. However, one well-designed study of 286 women with SCD concluded that rates of maternal morbidity from SCD were the same during pregnancy as during the nonpregnant state [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18430844\">",
"    <span class=\"h3\">",
"     Pregnancy outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project described above also reported pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/3\">",
"     3",
"    </a>",
"    ]. Compared with pregnant women without SCD, women with SCD were at increased risk of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intrauterine growth restriction (OR 2.2; 95% CI 1.8-2.6)",
"     </li>",
"     <li>",
"      Eclampsia (OR 3.2; 95% CI 1.8-6.0)",
"     </li>",
"     <li>",
"      Gestational hypertension and preeclampsia (OR 1.2; 95% CI 1.1-1.3)",
"     </li>",
"     <li>",
"      Preterm labor (OR 1.4; 95% CI 1.3-1.6)",
"     </li>",
"     <li>",
"      Postpartum infection (OR 1.4; 95% CI 1.1-1.7)",
"     </li>",
"     <li>",
"      Abruption (OR 1.6; 95% CI 1.2-2.1)",
"     </li>",
"     <li>",
"      Antepartum bleeding (OR 1.7; 95% CI 1.2-2.2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women with SCD had a lower rate of postpartum hemorrhage (OR 0.5; 95% CI 0.3-0.6). There was no statistical difference in rates of gestational diabetes (OR 1.0; 95% CI 0.8-1.2) or intrauterine fetal death (OR 1.1; 95% CI 0.8-1.7).",
"   </p>",
"   <p>",
"    Medical and obstetrical complications would be expected to result in an increased risk of preterm birth less than 37 weeks. In a study from Grady Hospital in Atlanta, SCD patients were four times more likely than African-American HbAA patients to have a preterm delivery, and their mean gestational age at delivery was 34.1 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/23\">",
"     23",
"    </a>",
"    ]. By comparison, in a study from Jamaica, preterm birth was threefold higher among SCD patients but the mean gestational age at delivery for SCD and HbAA patients was 37.0 and 38.7 weeks, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospital discharge data do not capture miscarriage rates, as many of these women are managed in nonhospital settings. In a cohort study, women with SCD (n=52 women, 94 pregnancies) had an increased rate of miscarriage compared with non-SCD controls (n=68 women, 157 pregnancies) (miscarriage: 36 percent versus 10 percent, p&lt;0.001).",
"   </p>",
"   <p>",
"    The cesarean delivery rate tends to be higher in women with SCD. The increased rate is related to a higher frequency of pregnancy complications, and some centers have policies for short trials of labor and early operative intervention at the first sign of a nonreassuring fetal heart rate tracing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056012\">",
"    <span class=\"h3\">",
"     Infant outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCD of the",
"    <span class=\"nowrap\">",
"     fetus/neonate",
"    </span>",
"    does not appear to influence birth outcome and neonatal course, when matched for gestational age and birthweight [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/25\">",
"     25",
"    </a>",
"    ]. This is because sickling events do not occur until the production of fetal hemoglobin is replaced by the production of hemoglobin S, which usually occurs between 3 and 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, life-threatening events, such as acute sequestration crisis, can occur in the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38937?source=see_link\">",
"     \"Routine comprehensive care for children with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1482541\">",
"    <span class=\"h3\">",
"     Effect of sickle disease genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have distinguished between the course of pregnancy for different SCD genotypes: hemoglobin (Hb) SS versus SC versus S-beta-thal. The course of pregnancy in women with HbSC is generally more benign than in those with HbSS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/15,28,29\">",
"     15,28,29",
"    </a>",
"    ]. In one cohort study, the frequency of miscarriage (12.5 percent) and live delivery (85 percent) in 95 pregnancies in women with HbSC disease was similar to that in 157 pregnancies in HbAA controls (miscarriage 10.4 percent, livebirth 89 percent) and significantly better than rates noted in 94 pregnancies in women with HbSS (miscarriage 36 percent, livebirth 57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the rates of painful crisis and acute chest syndrome were similar in the HbSC and HbSS pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1482623\">",
"    <span class=\"h3\">",
"     Effect of sickle cell trait",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether women with sickle cell trait (SCT) are at increased risk for pregnancy complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/30\">",
"     30",
"    </a>",
"    ]. In a systematic review including nine studies, some studies showed a protective effect of SCT for premature birth and stillbirth, and some showed an increased risk of anemia and bacteriuria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/31\">",
"     31",
"    </a>",
"    ]. However, given the poor methodological quality of most of these studies, the results are difficult to interpret.",
"   </p>",
"   <p>",
"    It is not clear whether these women require any modification to routine pregnancy care because of SCT. Because of the potentially increased risk of venous thrombosis in African Americans and women with SCT, we stress leg exercises, preventive anti-embolism stockings, and sequential compression devices in individuals requiring bedrest, as well as resumption of ambulation as early as possible. We follow the recommendations for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    use for high risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/32\">",
"     32",
"    </a>",
"    ]. Because individuals with SCT are at risk for bacteruria and hematuria, we obtain a detailed history of any previous urinary abnormalities. If the history or initial urine screening tests are abnormal, we perform frequent surveillance testing.",
"   </p>",
"   <p>",
"    It is important to test the patient&rsquo;s partner for hemoglobinopathy since their offspring would be a risk of homozygous hemoglobinopathy if both parents are carriers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24999?source=see_link&amp;anchor=H10#H10\">",
"     \"Prenatal testing for the hemoglobinopathies and thalassemias\", section on 'Identifying at-risk couples'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If some or all of the baseline evaluation was not performed pre-pregnancy, the missing assessments should be performed in early pregnancy. (See",
"    <a class=\"local\" href=\"#H18428063\">",
"     'Prepregnancy evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058765\">",
"    <span class=\"h2\">",
"     Prenatal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although complications are observed more frequently in women with HbSS than HbSC or",
"    <span class=\"nowrap\">",
"     HbS/beta-thal,",
"    </span>",
"    the level of care in pregnancy is the same for all of these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition to routine prenatal care, the following considerations apply to pregnant women with SCD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link\">",
"     \"Initial prenatal assessment and patient education\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44807?source=see_link\">",
"     \"Prenatal care (after initial prenatal assessment)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ideally, prenatal, intrapartum, and postpartum care are provided by a multidisciplinary team experienced in caring for women and pregnancies complicated by SCD. It is useful to have a patient care plan available to all clinicians who may be responsible for the patient if she has a painful crisis. This individualized plan should provide narcotic doses, an algorithm for sending the patient to the emergency department, and instructions for the emergency department.",
"     </li>",
"     <li>",
"      We suggest monthly determination of hemoglobin level, and chemistry panel. In our experience, these screening tests help with early identification of patients at greater risk for acute complications. While not prospectively evaluated, a similar approach has been adopted in the United Kingdom guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iron deficiency is not common in women with SCD, even those who are anemic, because chronic hemolysis and repeated blood transfusions often result in adequate or excessive iron stores. Therefore, iron supplementation is avoided unless iron deficiency is documented by a low serum ferritin level [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H27#H27\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      supplementation should be continued during pregnancy (see",
"      <a class=\"local\" href=\"#H18428094\">",
"       'Management of medications and immunization'",
"      </a>",
"      above). No dose finding studies have been performed. A dose of 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      has been recommended as likely to satisfy all of these needs [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"       4",
"      </a>",
"      ]. This is higher than the dose found in prenatal vitamins (1 mg).",
"     </li>",
"     <li>",
"      Nausea and vomiting of pregnancy is common in all pregnant women. Control of symptoms, especially prevention of dehydration from anorexia or vomiting, may help to decrease the incidence of painful crises [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=see_link\">",
"       \"Treatment and outcome of nausea and vomiting of pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are no strong data to guide the frequency of screening for asymptomatic bacteriuria or the optimum approach to treatment. We therefore recommend baseline and serial screening with urinalysis and culture [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/3\">",
"       3",
"      </a>",
"      ]. For women with asymptomatic bacteriuria on initial urine culture, we prescribe a course of antibiotic therapy and retest monthly until delivery. If they have recurrent or persistent bacteriuria, we give suppressive therapy for the remainder of pregnancy. For women whose initial urine culture is negative, some clinicians screen each trimester, and others, including the author, rescreen monthly [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=see_link&amp;anchor=H11#H11\">",
"       \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\", section on 'Suppressive therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Close monitoring for development of preeclampsia is a standard part of prenatal care in all pregnancies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11480?source=see_link&amp;anchor=H15#H15\">",
"       \"Prediction of preeclampsia\", section on 'Pregnancy management'",
"      </a>",
"      .) Given the increased risk of preeclampsia, some authors suggest daily use of low dose (75 mg)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      to reduce this risk [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=see_link&amp;anchor=H9#H9\">",
"       \"Prevention of preeclampsia\", section on 'Approach to therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients with neurological signs and symptoms, it is important to distinguish",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia",
"      </span>",
"      from cerebrovascular disease related to SCD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link\">",
"       \"Cerebrovascular complications of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given the possibility of placental ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/34,35\">",
"       34,35",
"      </a>",
"      ], monitoring fetal growth with ultrasound and fetal well-being with nonstress tests or biophysical profile scoring is reasonable during the third trimester. There are no high quality data on which to base recommendations for the optimum method and frequency of screening for fetal growth restriction and fetal hypoxemia.",
"      <br/>",
"      <br/>",
"      A guideline from the United Kingdom suggests ultrasound examinations at weeks 11 to 13 to establish the estimated date of delivery and screen for Down syndrome; weeks 18 to 20 to screen for congenital anomalies; and weeks 28, 32, and 36 to screen for fetal growth restriction [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link\">",
"       \"Diagnosis of fetal growth restriction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link\">",
"       \"Overview of fetal assessment\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If placental ischemia is suspected because of impaired fetal growth, preeclampsia, or abruption, management is the same as that for non-SCD pregnancies with these complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"       \"Fetal growth restriction: Evaluation and management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"       \"Preeclampsia: Management and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34663?source=see_link\">",
"       \"Placental abruption: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with SCD have a high rate of alloimmunization, which should be assessed at the first prenatal visit. If negative initially, we usually repeat such testing at 24 to 28 weeks and again when the patient is admitted at the time of delivery.",
"      <br/>",
"      <br/>",
"      Women with alloantibodies should be evaluated for risk of hemolytic disease of the fetus and newborn, and managed accordingly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"       \"Significance of minor red blood cell antibodies during pregnancy\"",
"      </a>",
"      .) In addition, the blood bank should be notified so compatible blood is available for transfusion, if needed peripartum. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"       \"Significance of minor red blood cell antibodies during pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=see_link&amp;anchor=H9#H9\">",
"       \"The incompatible crossmatch\", section on 'Sickle cell disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H27#H27\">",
"       \"Overview of the management of sickle cell disease\", section on 'Alloimmunization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple gestation &mdash; In our experience, multiple gestation in women with SCD substantially increases the risk of preeclampsia, hypertension, vasoocclusive crises, and acute anemic events; therefore, these pregnancies require close attention. We suggest early admission for vasoocclusive events. Prophylactic transfusion therapy should be considered in all women with preexisting cardiac, renal, or pulmonary complications, including a history of frequent acute chest syndrome and painful events (see",
"      <a class=\"local\" href=\"#H1059452\">",
"       'Prophylactic transfusion'",
"      </a>",
"      below). These patients should be followed closely at a tertiary obstetrical center with a hematologist with expertise in managing SCD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058980\">",
"    <span class=\"h2\">",
"     Management of acute painful episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dehydration, hypoxia, acidosis, infection, and cold may precipitate painful crisis; therefore, these conditions should be avoided, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2009 Cochrane systematic review did not find any randomized trials addressing the efficacy and safety of treatment approaches for painful sickle crisis during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/36\">",
"     36",
"    </a>",
"    ]. The standard approach to management consists of prompt evaluation for precipitating factors (eg, dehydration, hypoxia) and potential causes (particularly infection), oral or intravenous fluid resuscitation, and aggressive pain control using opioids, other analgesics, or other modalities (eg, epidural analgesia) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/37\">",
"     37",
"    </a>",
"    ]. This approach is similar to that in nonpregnant women, except nonsteroidal antiinflammatory drugs (NSAIDs) are generally avoided after 30 weeks of gestation because of an increased risk of&nbsp;premature narrowing or closure of the ductus arteriosus. Opioids are the mainstay of treatment of acute painful episodes in both pregnant and nonpregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17114?source=see_link\">",
"     \"Acute pain management in adults with sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18580098\">",
"    <span class=\"h2\">",
"     Management of other complications of SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of other complications of SCD is generally similar to that in nonpregnant women. The risks of specific medications used to treat these complications in pregnant women can be checked by searching on the drug name in UpToDate and reading the pregnancy implications section of the drug information topic. The pregnancy risks need to be weighed against the risks of alternative medications or no treatment. Although the safety of radiation exposure during pregnancy is a common concern, a missed or delayed diagnosis can pose a greater risk to the woman and her pregnancy than any hazard associated with ionizing radiation from diagnostic studies, such chest x-ray,",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    lung scanning, computed tomographic pulmonary angiography (CTPA), or digital subtraction angiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link&amp;anchor=H11#H11\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\", section on 'Radiographic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard differential diagnosis of SCD complications should be expanded to include pregnancy-related disorders. For example, neurological symptoms may be related to",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia,",
"    </span>",
"    and liver function abnormalities and hemolysis may be related to HELLP syndrome.",
"   </p>",
"   <p>",
"    The majority of deaths during pregnancy in SCD are sudden. Acute pulmonary failure, often associated with acute chest syndrome or pulmonary embolism, is commonly described [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/26,38,39\">",
"     26,38,39",
"    </a>",
"    ]. These patients often have acute multi-organ failure. Neurologic events may be part of the multi-organ syndrome or present as independent ischemic episodes.",
"   </p>",
"   <p>",
"    These life-threatening events may be preceded by acute painful episodes, so it is important to effectively treat vasoocclusive crises and monitor for early signs of life-threatening events. Patients hospitalized with a painful event should receive intravenous fluids and oxygen therapy as needed to maintain intravascular volume and oxygenation. Early evidence of impaired pulmonary, hepatic, renal, or CNS function should be considered a signal of an impending life-threatening event; an investigation for the cause of the worsening function (such as acute chest syndrome, pulmonary embolism, cerebral ischemia, cardiomyopathy, pulmonary hypertension, HELLP) should be undertaken immediately. Transfusion therapy is often necessary before completion of the evaluation and the differential diagnosis to halt disease progression.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9066?source=see_link\">",
"       \"Acute chest syndrome in adults with sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link\">",
"       \"Cerebrovascular complications of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39961?source=see_link\">",
"       \"Management of fever in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2842?source=see_link\">",
"       \"Hepatic manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link\">",
"       \"Pulmonary complications of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18506?source=see_link\">",
"       \"Bone and joint complications in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059444\">",
"    <span class=\"h2\">",
"     Transfusion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion therapy is commonly used during pregnancy to treat acute complications, in preparation for surgery, and in selected preventive transfusion programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059452\">",
"    <span class=\"h3\">",
"     Prophylactic transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prophylactic blood transfusions to reduce complications of pregnancy in patients with SCD is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/40-43\">",
"     40-43",
"    </a>",
"    ], as available data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/44\">",
"     44",
"    </a>",
"    ]. In the seminal randomized trial including 72 pregnant patients with SCD, women treated with routine prophylactic transfusions had no difference in most medical, obstetrical, and neonatal outcomes compared with those who were treated only for",
"    <span class=\"nowrap\">",
"     medical/obstetrical",
"    </span>",
"    emergencies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/43\">",
"     43",
"    </a>",
"    ]. The number of subjects and events was small, so only large differences in these outcomes would achieve statistical significance. However, one significant benefit of routine prophylactic transfusion was observed: a reduction in incidence of painful crises",
"    <span class=\"nowrap\">",
"     (5/36",
"    </span>",
"    [14 percent] versus",
"    <span class=\"nowrap\">",
"     18/36",
"    </span>",
"    [50 percent], p&lt;0.01). This advantage must be weighed against the associated increases in cost, number of hospitalizations, and risk of alloimmunization (29 percent versus 21 percent with indicated transfusion).",
"   </p>",
"   <p>",
"    Although not evaluated in randomized trials, some experts believe that selective use of prophylactic transfusion may be useful in pregnant women with SCD at highest risk of complications, such as those with previous perinatal mortality or severe anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4,41,42\">",
"     4,41,42",
"    </a>",
"    ]. These transfusions are performed on an outpatient basis every three to four weeks to keep hemoglobin &ge;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and &lt;12.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and hemoglobin S below 35 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/21,26,40,43\">",
"     21,26,40,43",
"    </a>",
"    ]. In the seminal trial described above, half the women received blood transfusion only if hemoglobin fell below 6",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and the other half received 2 units of blood every week for three weeks or until their hemoglobin level was 10 to 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We follow a policy in which most SCD (hemoglobin SS) patients receive transfusion therapy in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/40\">",
"     40",
"    </a>",
"    ]. In high-risk patients with chronic organ dysfunction or significant history of acute chest syndrome and painful events, we initiate transfusion early in pregnancy. In patients with mild hemoglobin variants, or a benign clinical history, prophylactic transfusions are not utilized.",
"   </p>",
"   <p>",
"    We recommend use of leukocyte-depleted red cell units phenotypically-matched for at least the C, E, and Kell blood groups. In chronically ill patients with high baseline hemoglobins, exchange transfusions are indicated to maintain the hemoglobin A level greater than 30 to 50 percent. Administration of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    may be needed to prevent fluid overload in patients with cardiac",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/21,26,40,45,46\">",
"     21,26,40,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059459\">",
"    <span class=\"h3\">",
"     Transfusion for acute complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with acute complications of SCD can benefit from transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/14,38\">",
"     14,38",
"    </a>",
"    ]. Accepted indications for therapeutic transfusion therapy in individuals with SCD include acute stroke, acute chest syndrome, acute multi-organ failure, acute symptomatic anemia (eg, onset of heart failure, dyspnea, hypotension, marked fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/47\">",
"     47",
"    </a>",
"    ]), reticulocytopenia (most commonly associated with Parvovirus B19 infection, but can occur with any infection), or following hepatic or splenic sequestration. Additional indications in",
"    <span class=\"nowrap\">",
"     pregnant/postpartum",
"    </span>",
"    women include prior to cesarean delivery and preeclampsia that does not improve after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/48\">",
"     48",
"    </a>",
"    ]. Transfusion techniques are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9066?source=see_link&amp;anchor=H25011400#H25011400\">",
"     \"Acute chest syndrome in adults with sickle cell disease\", section on 'Transfusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the management of sickle cell disease\", section on 'Transfusion therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18078415\">",
"    <span class=\"h2\">",
"     Labor and vaginal delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no medical contraindications to vaginal delivery. No high quality studies have evaluated the optimum gestational age for delivery. In the absence of maternal or fetal complications, awaiting spontaneous labor is reasonable. Induction of labor and cesarean delivery are performed only for the usual obstetrical indications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During labor and delivery the parturient should be kept well oxygenated (O",
"    <sub>",
"     2",
"    </sub>",
"    saturation &ge;95 percent), warm, and hydrated to prevent sickling. We suggest continuous fetal heart rate monitoring since these pregnancies are at higher risk of complications (see",
"    <a class=\"local\" href=\"#H18430844\">",
"     'Pregnancy outcome'",
"    </a>",
"    above). Neuraxial anesthesia is useful to reduce maternal cardiac demands secondary to labor pain and anxiety. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3657?source=see_link\">",
"     \"Obstetric anesthetic management of women with acquired or congenital heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059872\">",
"    <span class=\"h2\">",
"     Cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimally, cesarean delivery can be scheduled, but labor complications may necessitate an intrapartum",
"    <span class=\"nowrap\">",
"     urgent/emergent",
"    </span>",
"    procedure. Preoperatively, the patient should be well-hydrated and oxygen saturation should be maintained at &ge;95 percent. If there is time, simple transfusion to achieve hemoglobin 10 to 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is reasonable in patients at increased risk of complications because of chronic lung disease, central nervous system disease, or multiorgan dysfunction. Regional anesthesia is generally safer and preferable to general anesthesia, but the choice is influenced by a variety of factors, such as the urgency of the procedure, maternal hemodynamic status, and physician and patient preference (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=see_link\">",
"     \"Anesthesia for cesarean delivery\"",
"    </a>",
"    ). Fluid balance is important because these patients are at risk for fluid retention from subclinical cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After cesarean delivery, both the American College of Chest Physicians (ACCP) and the National Health Service (NHS) of the United Kingdom suggest pharmacologic thromboprophylaxis (low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [LMWH]) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4,50\">",
"     4,50",
"    </a>",
"    ]. Mechanical thromboprophylaxis (thromboembolism stockings, pneumatic compression) is recommended for women who have contraindications to anticoagulation, and is suggested in addition to anticoagulation for patients at highest risk of VTE because of multiple risk factors. At a minimum, thromboprophylaxis is administered while the patient is in the hospital, and should be continued up to six weeks postpartum for patients with ongoing risk factors for VTE following delivery (eg, reduced mobility, infection, transfusion, re-admission). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link&amp;anchor=H4#H4\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\", section on 'Postpartum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1484929\">",
"    <span class=\"h2\">",
"     Cord blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cord blood specimen collected at the time of delivery is helpful for establishing the nature of the hemoglobinopathy present in the newborn and educating the parents about the possible need for specialized pediatric care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of sickle cell syndromes\", section on 'Newborn screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38937?source=see_link\">",
"     \"Routine comprehensive care for children with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Umbilical cord blood also may be harvested for stem cells for future transplantation of a family member with SCD. This option should be discussed before pregnancy or in early pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=see_link\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POSTPARTUM MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18579183\">",
"    <span class=\"h2\">",
"     Postpartum care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close maternal surveillance for infection and thromboembolism and initiation of measures to prevent these complications are important, especially in women who deliver by cesarean. Anorexia, nausea, urinary tract infection, wound infection, endometritis, and venous thromboembolism (VTE) are more common after cesarean than vaginal birth; the risk of VTE is estimated at &gt;3 percent in women with a major risk factor for VTE (eg, SCD) who undergo cesarean [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preventive measures for all postpartum women with SCD include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic prophylaxis per local standards. In the US, one dose of prophylactic antibiotics is administered prior to all cesarean deliveries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=see_link&amp;anchor=H9#H9\">",
"       \"Cesarean delivery: Preoperative issues\", section on 'Antibiotic prophylaxis'",
"      </a>",
"      .) In the UK, broad-spectrum antibiotics (eg, augmentin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ) are recommended for labor and delivery and for five days post delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adequate fluid intake so the mother is well hydrated. This may necessitate intravenous fluid administration and anti-emetic therapy until oral intake is adequate.",
"     </li>",
"     <li>",
"      Adequate oxygenation (O",
"      <sub>",
"       2",
"      </sub>",
"      saturation &ge;95 percent). Supplemental oxygen should be given, as needed. Continuous positive airway pressure (CPAP) should be considered if chest signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms develop, or oxygen saturation falls below 92 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early ambulation and thromboembolism prophylaxis. Anticoagulation is probably not indicated after vaginal delivery because the risk of VTE is much lower than after cesarean delivery, although higher than during the antepartum period. However, anticoagulation may be indicated based on patient specific risk factors. No guidelines are available.",
"      <br/>",
"      <br/>",
"      Thromboembolism prophylaxis for patients undergoing cesarean delivery is described above (see",
"      <a class=\"local\" href=\"#H1059872\">",
"       'Cesarean delivery'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1710611\">",
"    <span class=\"h2\">",
"     Resumption of medications for SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following delivery, we re-start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    at the steady state dose the patient was on prenatally, if she is not breastfeeding. In women who were on iron chelators pre-pregnancy, iron status should be re-evaluated postpartum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18579190\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobinopathy is not a contraindication to breastfeeding, which should be encouraged for its maternal and infant health benefits, except in mothers taking medications that are transferred into breast milk and considered potentially harmful to the infant (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ). The safety of medication use in breastfeeding mothers can be checked by searching on the drug name in UpToDate and reading the lactation section of the drug information topic, or by searching on the drug name in other resources, such as",
"    <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\">",
"     LactMed",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=see_link\">",
"     \"Maternal and economic benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=see_link\">",
"     \"Breastfeeding: Parental education and support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2012 systematic review including eight studies found no evidence that hormonal contraception use in women with SCD increased their risk of clinical complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/51\">",
"     51",
"    </a>",
"    ]. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) consider all methods of combined (estrogen-progestin) and progestin-only hormonal contraception and the copper-releasing IUD safe and effective for women with SCD (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78542 \" href=\"UTD.htm?22/49/23324\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is limited evidence that the use of depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA) reduces the frequency of painful crises (OR 0.23; 95% CI 0.05-1.02; one randomized trial, 25 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1483728\">",
"    <span class=\"h2\">",
"     Infant care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to routine care, the neonate should be tested for hemoglobinopathy. Neonates with SCD do not have sickling events until the production of fetal hemoglobin is replaced by the production of hemoglobin S, which usually occurs between 3 to 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/62/20458/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38937?source=see_link&amp;anchor=H112753063#H112753063\">",
"     \"Routine comprehensive care for children with sickle cell disease\", section on 'Newborn screening follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/8/4227?source=see_link\">",
"       \"Patient information: Sickle cell anemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18580424\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the risks of pregnancy to women with sickle cell disease (SCD) and the fetus, preconceptional evaluation and counseling should be performed. This includes (see",
"      <a class=\"local\" href=\"#H1011610\">",
"       'Prepregnancy issues'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Evaluation of the patient&rsquo;s baseline status. (See",
"      <a class=\"local\" href=\"#H18428063\">",
"       'Prepregnancy evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing the patient&rsquo;s partner for hemoglobinopathy to determine type and risk of inherited disease in offspring, followed by genetic counseling. (See",
"      <a class=\"local\" href=\"#H1482781\">",
"       'Genetic counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discontinuing medications contraindicated in pregnancy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      , iron chelation, angiotensin converting enzyme inhibitors and angiotensin II receptor blockers) and bringing immunizations up to date. (See",
"      <a class=\"local\" href=\"#H18428094\">",
"       'Management of medications and immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Providing information on the course of SCD in pregnancy, the effect of SCD on pregnancy, and infant outcome. (See",
"      <a class=\"local\" href=\"#H18429102\">",
"       'Counseling about medical, obstetrical, and infant outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SCD can be diagnosed preimplantation or prenatally. Prevention of an affected pregnancy is possible by a variety of assisted reproductive techniques. (See",
"      <a class=\"local\" href=\"#H1483024\">",
"       'Preimplantation diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1483082\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe anemia and vasoocclusive or painful crises are more common in pregnancy. As in nonpregnant women, severe pain should be managed with opioids. (See",
"      <a class=\"local\" href=\"#H1058980\">",
"       'Management of acute painful episodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modifications of prenatal care for women with SCD include an increased dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplement (5",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      checking ferritin level and only giving iron supplements or prenatal vitamins with iron if the patient is iron deficient, increased frequency of screening for asymptomatic bacteriuria, ultrasound screening for fetal growth restriction, and fetal assessment in the third trimester. (See",
"      <a class=\"local\" href=\"#H1058765\">",
"       'Prenatal care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alloimmunization should be assessed at the first prenatal visit. If negative initially, we usually repeat such testing at 24 to 28 weeks and again at the time of delivery.",
"      <br/>",
"      <br/>",
"      Women with alloantibodies should be evaluated for risk of hemolytic disease of the fetus and newborn, and managed accordingly. In addition, the blood bank should be notified so that compatible blood is available for transfusion, if needed. (See",
"      <a class=\"local\" href=\"#H1058765\">",
"       'Prenatal care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate hydration and oxygenation, keeping warm, and measures to reduce infection are important to reduce the risk of vasoocclusion. The management of painful vasoocclusive episodes is the same as that in nonpregnant women, except nonsteroidal antiinflammatory drugs (NSAIDs) are generally avoided after 30 weeks of gestation because of an increased risk of&nbsp;premature narrowing or closure of the ductus arteriosus. Opioids are the mainstay of therapy in pregnant and nonpregnant women. (See",
"      <a class=\"local\" href=\"#H1058980\">",
"       'Management of acute painful episodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In SCD patients at high risk of complications, we suggest prophylactic transfusion therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Transfusion therapy should be individualized with involvement of a multidisciplinary team. (See",
"      <a class=\"local\" href=\"#H1059452\">",
"       'Prophylactic transfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no medical contraindications to vaginal delivery. In the absence of maternal or fetal complications, awaiting spontaneous labor is reasonable. &nbsp;Induction of labor and cesarean delivery are performed only for the usual obstetrical indications. (See",
"      <a class=\"local\" href=\"#H18078415\">",
"       'Labor and vaginal delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who undergo cesarean delivery, we suggest postpartum prophylactic anticoagulation with low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18579183\">",
"       'Postpartum care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hormonal contraceptives and the copper-releasing intrauterine device (IUD) are safe and effective methods for women with SCD. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Contraception'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/1\">",
"      Smith JA, Espeland M, Bellevue R, et al. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Obstet Gynecol 1996; 87:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/2\">",
"      Serjeant GR, Loy LL, Crowther M, et al. Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol 2004; 103:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/3\">",
"      Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 2008; 199:125.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Pregnancy, contraception and fertility. In: Standards for the Clinical Care of Adults with Sickle Cell Disease in the UK, 2008. p.59.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/5\">",
"      Morris RK, Riley RD, Doug M, et al. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ 2012; 345:e4342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/6\">",
"      Kuliev A, Pakhalchuk T, Verlinsky O, Rechitsky S. Preimplantation genetic diagnosis for hemoglobinopathies. Hemoglobin 2011; 35:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/7\">",
"      Barrett AN, McDonnell TC, Chan KC, Chitty LS. Digital PCR analysis of maternal plasma for noninvasive detection of sickle cell anemia. Clin Chem 2012; 58:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/8\">",
"      Phylipsen M, Yamsri S, Treffers EE, et al. Non-invasive prenatal diagnosis of beta-thalassemia and sickle-cell disease using pyrophosphorolysis-activated polymerization and melting curve analysis. Prenat Diagn 2012; 32:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/9\">",
"      Wang X, Seaman C, Paik M, et al. Experience with 500 prenatal diagnoses of sickle cell diseases: the effect of gestational age on affected pregnancy outcome. Prenat Diagn 1994; 14:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/10\">",
"      Santana DS, Cecatti JG, Parpinelli MA, et al. Severe maternal morbidity due to abortion prospectively identified in a surveillance network in Brazil. Int J Gynaecol Obstet 2012; 119:44.",
"     </a>",
"    </li>",
"    <li>",
"     www.reprotox.org (Accessed on September 20, 2012).",
"    </li>",
"    <li>",
"     Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 8th edition, Lippincott Williams &amp; Wilkins.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/13\">",
"      Singer ST, Vichinsky EP. Deferoxamine treatment during pregnancy: is it harmful? Am J Hematol 1999; 60:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/14\">",
"      Howard J, Oteng-Ntim E. The obstetric management of sickle cell disease. Best Pract Res Clin Obstet Gynaecol 2012; 26:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/15\">",
"      Powars DR, Sandhu M, Niland-Weiss J, et al. Pregnancy in sickle cell disease. Obstet Gynecol 1986; 67:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/16\">",
"      Adams S. Caring for the pregnant woman with sickle cell crisis. Prof Care Mother Child 1996; 6:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/17\">",
"      Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol 2003; 120:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/18\">",
"      Martin JN Jr, Martin RW, Morrison JC. Acute management of sickle cell crisis in pregnancy. Clin Perinatol 1986; 13:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/19\">",
"      Al Jama FE, Gasem T, Burshaid S, et al. Pregnancy outcome in patients with homozygous sickle cell disease in a university hospital, Eastern Saudi Arabia. Arch Gynecol Obstet 2009; 280:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/20\">",
"      Rajab KE, Issa AA, Mohammed AM, Ajami AA. Sickle cell disease and pregnancy in Bahrain. Int J Gynaecol Obstet 2006; 93:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/21\">",
"      Ng&ocirc; C, Kayem G, Habibi A, et al. Pregnancy in sickle cell disease: maternal and fetal outcomes in a population receiving prophylactic partial exchange transfusions. Eur J Obstet Gynecol Reprod Biol 2010; 152:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/22\">",
"      Al Kahtani MA, AlQahtani M, Alshebaily MM, et al. Morbidity and pregnancy outcomes associated with sickle cell anemia among Saudi women. Int J Gynaecol Obstet 2012; 119:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/23\">",
"      Sun PM, Wilburn W, Raynor BD, Jamieson D. Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol 2001; 184:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/24\">",
"      Koshy M, Chisum D, Burd L, et al. Management of sickle cell anemia and pregnancy. J Clin Apher 1991; 6:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/25\">",
"      Brown AK, Sleeper LA, Pegelow CH, et al. The influence of infant and maternal sickle cell disease on birth outcome and neonatal course. Arch Pediatr Adolesc Med 1994; 148:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/26\">",
"      Hassell K. Pregnancy and sickle cell disease. Hematol Oncol Clin North Am 2005; 19:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/27\">",
"      Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988; 81:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/28\">",
"      Milner PF, Jones BR, D&ouml;bler J. Outcome of pregnancy in sickle cell anemia and sickle cell-hemoglobin C disease. An analysis of 181 pregnancies in 98 patients, and a review of the literature. Am J Obstet Gynecol 1980; 138:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/29\">",
"      Serjeant GR, Hambleton I, Thame M. Fecundity and pregnancy outcome in a cohort with sickle cell-haemoglobin C disease followed from birth. BJOG 2005; 112:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/30\">",
"      Goldsmith JC, Bonham VL, Joiner CH, et al. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. Am J Hematol 2012; 87:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/31\">",
"      Jans SM, de Jonge A, Lagro-Janssen AL. Maternal and perinatal outcomes amongst haemoglobinopathy carriers: a systematic review. Int J Clin Pract 2010; 64:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/32\">",
"      Buckner TW, Key NS. Venous thrombosis in blacks. Circulation 2012; 125:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/33\">",
"      Abudu OO, Macaulay K, Oluboyede OA. Serial evaluation of iron stores in pregnant Nigerians with hemoglobin SS or SC. J Natl Med Assoc 1990; 82:41.",
"     </a>",
"    </li>",
"    <li>",
"     Benirschke K, Kaufmann P, Baergen R. Pathology of the Human Placenta, 5th edition, Springer, 2006. p.592.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/35\">",
"      Rathod KB, Jaiswal KN, Shrivastava AC, Shrikhande AV. Study of placenta in sickle cell disorders. Indian J Pathol Microbiol 2007; 50:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/36\">",
"      Mart&iacute;-Carvajal AJ, Pe&ntilde;a-Mart&iacute; GE, Comuni&aacute;n-Carrasco G, Mart&iacute;-Pe&ntilde;a AJ. Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database Syst Rev 2009; :CD006786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/37\">",
"      Winder AD, Johnson S, Murphy J, Ehsanipoor RM. Epidural analgesia for treatment of a sickle cell crisis during pregnancy. Obstet Gynecol 2011; 118:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/38\">",
"      Asnani MR, McCaw-Binns AM, Reid ME. Excess risk of maternal death from sickle cell disease in Jamaica: 1998-2007. PLoS One 2011; 6:e26281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/39\">",
"      Rogers DT, Molokie R. Sickle cell disease in pregnancy. Obstet Gynecol Clin North Am 2010; 37:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/40\">",
"      Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol 1995; 102:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/41\">",
"      Koshy M. Sickle cell disease and pregnancy. Blood Rev 1995; 9:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/42\">",
"      Grossetti E, Carles G, El Guindi W, et al. Selective prophylactic transfusion in sickle cell disease. Acta Obstet Gynecol Scand 2009; 88:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/43\">",
"      Koshy M, Burd L, Wallace D, et al. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med 1988; 319:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/44\">",
"      Mahomed K. Prophylactic versus selective blood transfusion for sickle cell anaemia during pregnancy. Cochrane Database Syst Rev 2000; :CD000040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/45\">",
"      Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995; 333:206.",
"     </a>",
"    </li>",
"    <li>",
"     Vichinsky E. Management and therapy of sickle cell disease. In: Publication No. 95-2117, 4th ed, Reid C, Charles S, Lubin B (Eds), U.S. Department of Health and Human Services, National Institutes of Health, 2002. p.153.",
"    </li>",
"    <li>",
"     The management of sickle cell disease. National Institutes of Health; National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources. NIH publication 04-2117, revised 2004. This reference is also available for downloading or purchase at: www.nhlbi.nih.gov/health/prof/blood/sickle/ (Accessed on June 25, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/48\">",
"      Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology Am Soc Hematol Educ Program 2005; :58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/49\">",
"      Voskaridou E, Christoulas D, Terpos E. Sickle-cell disease and the heart: review of the current literature. Br J Haematol 2012; 157:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/50\">",
"      Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/51\">",
"      Haddad LB, Curtis KM, Legardy-Williams JK, et al. Contraception for individuals with sickle cell disease: a systematic review of the literature. Contraception 2012; 85:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/62/20458/abstract/52\">",
"      Manchikanti A, Grimes DA, Lopez LM, Schulz KF. Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev 2007; :CD006261.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7139 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20458=[""].join("\n");
var outline_f19_62_20458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18580424\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1011610\">",
"      PREPREGNANCY ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18428063\">",
"      Prepregnancy evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1482781\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1483024\">",
"      - Preimplantation diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1483082\">",
"      - Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18428094\">",
"      Management of medications and immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18429102\">",
"      Counseling about medical, obstetrical, and infant outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18429428\">",
"      - SCD course during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18430844\">",
"      - Pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056012\">",
"      - Infant outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1482541\">",
"      - Effect of sickle disease genotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1482623\">",
"      - Effect of sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1058765\">",
"      Prenatal care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1058980\">",
"      Management of acute painful episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18580098\">",
"      Management of other complications of SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1059444\">",
"      Transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1059452\">",
"      - Prophylactic transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1059459\">",
"      - Transfusion for acute complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18078415\">",
"      Labor and vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1059872\">",
"      Cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1484929\">",
"      Cord blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POSTPARTUM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18579183\">",
"      Postpartum care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1710611\">",
"      Resumption of medications for SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18579190\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1483728\">",
"      Infant care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18580424\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7139\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7139|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 2\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/49/23324\" title=\"table 3\">",
"      WHO MEC for thalassemia and sickle cell disease and anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9066?source=related_link\">",
"      Acute chest syndrome in adults with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17114?source=related_link\">",
"      Acute pain management in adults with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=related_link\">",
"      Anesthesia for cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18506?source=related_link\">",
"      Bone and joint complications in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=related_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11433?source=related_link\">",
"      Donor insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2842?source=related_link\">",
"      Hepatic manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39961?source=related_link\">",
"      Management of fever in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=related_link\">",
"      Maternal and economic benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3657?source=related_link\">",
"      Obstetric anesthetic management of women with acquired or congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/8/4227?source=related_link\">",
"      Patient information: Sickle cell anemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34663?source=related_link\">",
"      Placental abruption: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11480?source=related_link\">",
"      Prediction of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22777?source=related_link\">",
"      Pregnancy in women with pre-existing chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44807?source=related_link\">",
"      Prenatal care (after initial prenatal assessment)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24999?source=related_link\">",
"      Prenatal testing for the hemoglobinopathies and thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38937?source=related_link\">",
"      Routine comprehensive care for children with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=related_link\">",
"      Sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=related_link\">",
"      Significance of minor red blood cell antibodies during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=related_link\">",
"      The incompatible crossmatch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=related_link\">",
"      Treatment and outcome of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=related_link\">",
"      Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=related_link\">",
"      Vasoocclusion in sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_62_20459="Antithyroid drug comparisons";
var content_f19_62_20459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antithyroid drug comparisons",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        PTU",
"       </td>",
"       <td class=\"subtitle1\">",
"        Methimazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Response time",
"       </td>",
"       <td>",
"        Slower",
"       </td>",
"       <td>",
"        Faster",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxicity",
"       </td>",
"       <td>",
"        Dose-related hepatitis, vasculitis",
"       </td>",
"       <td>",
"        Dose-related, rare side-effects less common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compliance",
"       </td>",
"       <td>",
"        Worse",
"       </td>",
"       <td>",
"        Better",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cost (monthly)",
"       </td>",
"       <td>",
"        $22 for 300 mg/day",
"       </td>",
"       <td>",
"        $62 for 30 mg/day; $21 for 10 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Effect on radioiodine outcome",
"       </td>",
"       <td>",
"        Decreases effect",
"       </td>",
"       <td>",
"        Possible effect",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Cooper DC. Antithyroid drugs in the management of patients with Graves' disease: An evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003; 88:3474. file://jcem.endojournals.org/. Copyright &copy; 2003 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20459=[""].join("\n");
var outline_f19_62_20459=null;
var title_f19_62_20460="Treatment of reflex syncope";
var content_f19_62_20460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of reflex syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Explanation of the diagnosis, provision of reassurance, and explanation of risk recurrence are indicated in all patients",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isometric PCMs are indicated in patients with prodrome",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac pacing should be considered in patients with dominant cardioinhibitory CSS",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac pacing should be considered in patients with frequent recurrent reflex syncope, age &gt;40 years, and documented spontaneous cardioinhibitory response during monitoring",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Midodrine may be indicated in patients with VVS refractory to lifestyle measures",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tilt training may be useful for education of patients but long-term benefit depends on compliance",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac pacing may be indicated in patients with tilt-induced cardioinhibitory response with recurrent frequent unpredictable syncope and age &gt;40 after alternative therapy has failed",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reflex",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &beta;-adrenergic blocking drugs are not indicated",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        A",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CSS: carotid sinus syndrome; PCM: physical isometric counterpressure manouuvre; VVS: vasovagal syncope.",
"     <br>",
"      * Class of recommendation.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Level of evidence.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20460=[""].join("\n");
var outline_f19_62_20460=null;
var title_f19_62_20461="Pharmacotherapy ASD";
var content_f19_62_20461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected pharmacotherapeutic agents used for symptom management in children and adolescents with autism spectrum disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Targeted symptom(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential adverse effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Atypical antipsychotic agents",
"        </strong>",
"        (eg, risperidone*, aripiprazole*, olanzapine)",
"       </td>",
"       <td>",
"        <p>",
"         Aggression",
"        </p>",
"        <p>",
"         Hyperactivity/inattention",
"        </p>",
"        <p>",
"         Repetitive behavior",
"        </p>",
"        <p>",
"         Sleep disturbance",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Weight gain",
"        </p>",
"        <p>",
"         Metabolic syndrome",
"        </p>",
"        <p>",
"         Tremor",
"        </p>",
"        <p>",
"         Extrapyramidal symptoms",
"        </p>",
"        <p>",
"         Increased salivation",
"        </p>",
"        <p>",
"         Sedation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stimulants",
"        </strong>",
"        (eg, methylphenidate, dextroamphetamine, dexmethylphenidate)",
"       </td>",
"       <td>",
"        Hyperactivity/inattention/impulsivity",
"       </td>",
"       <td>",
"        <p>",
"         Decreased appetite",
"        </p>",
"        <p>",
"         Difficulty falling asleep",
"        </p>",
"        <p>",
"         Irritability",
"        </p>",
"        <p>",
"         Social withdrawal",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Selective serotonin reuptake inhibitors",
"        </strong>",
"        (eg, fluoxetine, fluvoxamine, sertraline, paroxetine, etc)",
"       </td>",
"       <td>",
"        <p>",
"         Aggression",
"        </p>",
"        <p>",
"         Anxiety",
"        </p>",
"        <p>",
"         Depression",
"        </p>",
"        <p>",
"         Repetitive behavior",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Potential increased risk of suicidal ideation",
"        </p>",
"        <p>",
"         Behavioral activation",
"        </p>",
"        <p>",
"         Irritability",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Alpha-2-adrenergic agonists",
"        </strong>",
"        (eg, guanfacine, clonidine)",
"       </td>",
"       <td>",
"        <p>",
"         Aggression",
"        </p>",
"        <p>",
"         Hyperactivity/inattention",
"        </p>",
"        <p>",
"         Sleep disturbance",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sedation",
"        </p>",
"        <p>",
"         Fatigue",
"        </p>",
"        <p>",
"         Irritability",
"        </p>",
"        <p>",
"         Constipation",
"        </p>",
"        <p>",
"         Hypotension",
"        </p>",
"        <p>",
"         Rebound hypertension if discontinued abruptly",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Anticonvulsant mood stabilizers",
"        </strong>",
"        (eg, valproic acid)",
"       </td>",
"       <td>",
"        <p>",
"         Aggression",
"        </p>",
"        <p>",
"         Hyperactivity/inattention",
"        </p>",
"        <p>",
"         Repetitive behaviors",
"        </p>",
"        <p>",
"         Sleep disturbance",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mood lability",
"        </p>",
"        <p>",
"         Fatigue",
"        </p>",
"        <p>",
"         Insomnia",
"        </p>",
"        <p>",
"         Diarrhea",
"        </p>",
"        <p>",
"         Weight gain",
"        </p>",
"        <p>",
"         Increased appetite",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Atomoxetine",
"        </strong>",
"       </td>",
"       <td>",
"        Hyperactivity/inattention",
"       </td>",
"       <td>",
"        <p>",
"         Potential increased risk of suicidal ideation",
"        </p>",
"        <p>",
"         Irritability",
"        </p>",
"        <p>",
"         Gastrointestinal symptoms",
"        </p>",
"        <p>",
"         Fatigue",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Melatonin",
"        </strong>",
"       </td>",
"       <td>",
"        Sleep disturbance",
"       </td>",
"       <td>",
"        <p>",
"         Difficulty waking",
"        </p>",
"        <p>",
"         Daytime sleepiness",
"        </p>",
"        <p>",
"         Enuresis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mood stabilizer",
"        </strong>",
"        (eg, lithium)",
"       </td>",
"       <td>",
"        Aggression",
"       </td>",
"       <td>",
"        <p>",
"         Weight gain",
"        </p>",
"        <p>",
"         Nausea",
"        </p>",
"        <p>",
"         Frequent urination",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Approved by the&nbsp;US Food and Drug Administration for the treatment of aggression and irritability in children with autism spectrum disorders.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains in child and adolescent autism. Lancet 2003; 362:732.",
"       </li>",
"       <li>",
"        Myers SM, Johnson CP, American Academy of Pediatrics Council on Children with Disabilities. Management of children with autism spectrum disorders. Pediatrics 2007; 120:1162.",
"       </li>",
"       <li>",
"        Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008; 16:97.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20461=[""].join("\n");
var outline_f19_62_20461=null;
var title_f19_62_20462="Metformin in type 2 DM II";
var content_f19_62_20462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metformin in overweight patients with type 2 diabetes mellitus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 299px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier plots of any diabetes-related death in 753 overweight patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study who were randomly assigned to either intensive therapy with metformin or to conventional treatment with diet; drugs were added if there were hyperglycemic symptoms or if the fasting blood glucose concentration was greater than 270 mg/dL (15 mmol/L). Another 951 overweight patients received intensive therapy with a sulfonylurea or insulin and are included in the analysis. Metformin was associated with a 42 percent reduction in any diabetes-related endpoint compared to conventional therapy (P = 0.02).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998; 352:854.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20462=[""].join("\n");
var outline_f19_62_20462=null;
var title_f19_62_20463="Adjuvant medical treatment of HER2-negative early breast cancer";
var content_f19_62_20463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Adjuvant medical treatment of HER2-negative early breast cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 601px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ER: estrogen receptor.",
"     <br/>",
"     * Select low risk patients may not require chemotherapy. See table above.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     These factors can be used to determine recurrence risk for patients with early breast cancer and categorize them as low, intermediate, or high risk. They must be balanced by patient factors (ie, age and performance status) and patient preference. The delineation of risk thresholds may be determined by institutional or physician-practice guidelines. Further information on prognostic variables and the approach to early HER2-negative early breast cancer is found with UpToDate. (Refer to UpToDate topics on adjuvant chemotherapy for early stage HER2-negative breast cancer.)",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_62_20463=[""].join("\n");
var outline_f19_62_20463=null;
